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 The purpose of these studies is to acquire a clearer understanding of cardiorenal 
syndrome.  Observations have been made showing a small percentage of patients suffer 
acute renal failure after undergoing cardiopulmonary bypass as well as patients in cardiac 
failure.  The same clinicians making these observations think the cause of the renal injury 
are cytokines released by the injured or ischemic myocardium, but there has been no 
research done to support or disprove this theory.  Because TNF-α is suspected to be the 
most potent cytokine released from the ischemic myocardium and the most likely to 
induce renal dysfunction, it is the focus of this study. 
 The specific aims of this research is to (1) illustrate that there is an increase in 
serum TNF-α after cardiac ischemia, (2) find if there is injury to the kidney, measured by 
apoptosis (cleaved PARP), due to coronary occlusion, (3) locate the renal cells being 
injured by cardiac ischemia, and (4) measure renal apoptotic signaling (caspases 2, 3, and 
9) after cardiac ischemia and examine the role of TNF-α in these activities.  An 
Ultrasensitive TNF-α ELISA kit is used to measure serum levels of TNF-α and Western 
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Cardiovascular disease is a leading cause of death worldwide and remains one of the 
major killers in modern society [1], [2].  In recent years it has become apparent that the 
loss of myocardial cells may play a major pathogenic role cardiac disease [2], and current 
evidence has implicated proinflammatory cytokines in the pathophysiology of cell death 
in cardiovascular disease.  Levels of these cytokines are shown to increase with cardiac 
ischemia during cardiopulmonary bypass (CPB) and myocardial infarction (MI) [3], [4], 
[5], [6], and also occurs in patients suffering from cardiac failure (CF) [7].  Studies have 
demonstrated the myocardium to be a major source of the cytokines tumor necrosis 
factor-α (TNF), interleukin (IL)-1, IL-6, and IL-8 [5], [6].  
Observations of renal dysfunction or renal failure have been made in a small 
percentage of patients following CPB [3], [4], [6] and in patients with heart failure [7].   
Some investigators feel there is a connection between heart and kidney dysfunction they 
call “cardiorenal syndrome,” and these researchers assume this connection is caused by 
the injured heart releasing cytokines that damage the kidney [3].   There has been no 
research done to either support or disprove this theory.   Studies done in our laboratory 
show that with induced cardiac ischemia there are increased levels of the cell death 
signaling proteins in the kidney cells. 
1.2 Hypothesis 
Renal injury, as indicated by apoptosis in the kidney, results from the production 
and release of cytokines due to cardiac ischemia.   
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1.3 Specific Aims 
1. To quantitate the levels of the cytokine TNF.  ELISA will be used to measure TNF in 
the blood after a myocardial infarction.   
2. To determine if apoptosis occurs I-n kidney cells as a result of cardiac ischemia, the 
cleaved form of poly ADP-ribose polymerase (PARP) will be assessed by Western 
blot analysis.   
3. To examine which cell types in the kidney show activation of pro-apoptotic proteins 
following cardiac ischemia, assays will be performed using immunohistochemistry 
probing with specific antibodies.   
4. To investigate apoptotic signaling in kidney tissue after induced cardiac ischemia as 
well as examine the role of TNF in these activities the following assays will be 
preformed: 
a. Western blot analysis will be utilized to find and measure levels of pro-
apoptotic signaling of the active forms of caspase 3, caspase 2, and caspase 9; 
activity known for TNF receptor signaling pathways (see Figure 1.). 
b. Inhibit the release of TNF from the injured myocardium via metalloproteinase 
inhibitor to determine pro-apoptotic protein levels of the active forms of 
caspase 3, caspase 2, caspase 9, and cleaved PARP using Western blot 
analysis. 
c. TNF infusion studies without induced cardiac ischemia to determine levels of 
pro-apoptotic protein levels of the active forms of caspase 3, caspase 2, 




Results of this research will give a better understanding of the mechanisms 
involved in renal dysfunction due to ischemic injury of the heart.  These studies will also 
show that with the increased production and release of cytokines because of cardiac 
ischemia, other organ systems such as the kidney can be targeted and cause further insult 
to an already compromised patient.  To improve a patient’s overall outcome from such 
events, further investigations as the result of these studies may produce treatments 
preventing the harmful effects caused by these cytokines. 
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Chapter II 
REVIEW OF LITERATURE 
 
2.1 Cardiorenal Syndrome 
 
Cardiorenal syndrome is a term used to describe the connection between heart and 
kidney dysfunction.  Investigators feel the tie between these two important organs is the 
release of proinflammatory cytokines from the injured myocytes.  These cytokines 
become systemic which in turn can cause damage to various renal cells.   Levels of these 
cytokines are shown to increase with cardiac ischemia during CPB and MI [3], [4], [5], 
[6], and also in patients suffering from CF [7].  Increased cytokines levels have been 
reflected in cardiac ischemic animal studies as well [8], [9], [10].  Research has revealed 
the myocardium to be a major source of the cytokines TNF, IL-1, IL-6, and IL-8 [4], [6].   
 The modern era of cardiac surgery began when the technique for CPB was 
introduced in the early 1950s [5].  CPB is a commonly used surgical heart procedures to 
maintain extracorporeal circulation.   The procedure involves a diversion of the blood 
flow returning to the heart through a pump oxygenator (heart-lung machine) and then 
returning it to the arterial side of the circulation [11].  Most cases of CPB are associated 
with aortic cross-clamping, which results in global myocardial ischemia [4].   Although 
CPB is fundamental for cardiac surgery, it is associated with substantial postoperative 
morbidity.  The release of cytokines during CPB can have deleterious effects on the heart 
and on other organs.  The release of proinflammatory cytokines, such as TNF, IL-1β, and 
IL-8, has been associated with the development of complications after CPB.  The levels 
of these proinflammatory cytokines have been correlated with the duration of cardiac 
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ischemia during CPB and may contribute to the development of multi organ failure [4] 
[5] . 
The cytokines implicated after cardiac ischemia in renal dysfunction include IL-1, 
IL-6, IL-8 and TNF—the same cytokines produced and released by injured myocardium.  
IL-1, IL-6 and TNF can stimulate the mesangial cells of the kidney to produce its own 
IL-6, IL-8, and TNF [12].  IL-1 can indirectly activate apoptosis as well as activate 
inflammation [13], and is associated with poor outcome in several human disorders [14].  
IL-1β and TNF have similar effects, despite having different receptors and different 
intracellular signaling pathways and activity.  IL-1β elicits many of the same effects as 
TNF when it is infused in humans [15].  IL-6 and IL-8 are potent chemoattractants [16],  
[17],  [5].  Increased IL-6 concentrations may mediate apoptotic signals in endothelial 
cells [13] and provoke cytokine cascades.  Excessive expression of IL-6 is associated 
with morbidity and mortality [18],  [19].  IL-8 as well as being a chemoattractant, it also 
enhances neutrophil function, expression of adhesion molecules, degranulation, and 
respiratory burst [15].  Finally, the cytokine TNF can be highly destructive to the kidney 
by reducing glomerular blood and glomerular filtration rate, inducing the synthesis of 
other proinflammatory mediators, increasing glomerular albumin permeability, causing 
glomerular fibrin deposition, and stimulating cellular infiltration.  Because TNF appears 
to be one of the most potent inflammatory mediators in terms of its ability to induce 
cardiac and renal dysfunction [3] it is the focus of this study.  This investigation looks at 
TNF and its role in cardiorenal syndrome by looking at TNF mechanisms of action that 




Apoptosis, or cell suicide, is a form of cell death that is morphologically and 
biochemically distinct from necrosis [20]—a rapid and irreversible process that occurs 
when cells are severely damaged [2].  Although the concept of apoptosis was introduced 
approximately 30 years ago, the mechanisms of how apoptosis is initiated and executed 
remained unclear until recently.  During the past eight years, tremendous progress has 
been made in understanding apoptosis as a result of molecular identification of the key 
components of this intracellular suicide program.  The core of this cell suicide program is 
evolutionarily conserved from worm to human  [20]. 
 Unlike necrosis, which is a passive and unregulated process, apoptosis is both 
energy dependent and highly regulated.  Apoptosis is controlled by a complex interaction 
of numerous prosurvival and prodeath signals.  These include the Bcl-2 family of 
proteins, which may be antiapoptotic or proapoptic, and exerts its effect primarily at the 
level of mitochondria.  Other important regulators of apoptosis are enzymes called 
caspases. [2].   
Apoptosis occurs when a cell dies through activation of an internally controlled 
suicide program.  It is a subtly orchestrated disassembly of cellular components designed 
to eliminate unwanted cells during embryogenesis and in various physiologic processes.  
Doomed cells are removed with minimum disruption to the surrounding tissue.  
Apoptosis also occurs, however, under pathologic conditions, in which it is sometimes 
accompanied by necrosis [16].  Survival signals from the cell’s environment and internal 
sensors for cellular integrity normally keep a cell’s apoptotic machinery in check.  In the 
event that a cell loses contact with its surroundings or sustains irreparable internal 
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damage, the cell initiates apoptosis.  A cell that simultaneously receives conflicting 
signals driving or attenuating its division cycle may also trigger apoptosis.  Yet another 
mechanism has evolved enabling an organism to actively direct individual cells to self-
destruct.  This kind of “instructive” apoptosis is important especially in the immune 
system.  Death receptors—cell surface receptors that transmit apoptosis signals initiated 
by specific “death ligands”—play a central role in instructive apoptosis.  These receptors 
can activate the death caspases within seconds of ligand binding, causing an apoptotic 
demise of the cell within hours [21].  
Once initiated, apoptotic events include DNA fragmentation, chromatin 
condensation, membrane blebbing, cell shrinkage, and disassembly into membrane-
enclosed vesicles (apoptotic bodies) [16], [2], [22],  [23].  In vivo, this process culminates 
with engulfment of apoptotic bodies by other cells, preventing complications that would 
result from a release of intracellular contents, or with the loss of cells in the lumen of 
organ systems such as the gastrointestinal tract or renal tubules.  These changes occur in a 
predictable, reproducible sequence and can be completed within 30 to 60 minutes [23]. 
Cell death, the ultimate result of cell injury, is one of the most crucial events in 
pathology affecting every cell type and is the major consequence of ischemia and 
immune reactions [16].  TNF, a component of the immune system, is a proinflammatory 
cytokine, which acts to increase its own production, as well as the synthesis of small 
inflammatory mediators.  TNF can also play a key role in apoptosis via its death receptor.  
These receptors can activate programmed cell death within seconds of ligand binding 
causing an apoptotic demise of the cell within hours [21]. 
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Myocardial TNF production is a potential source of systemic TNF affecting 
myocardial and renal function due to its apoptotic contribution.  Renal cell apoptosis is 
the likely cause of renal cell death during acute renal failure following cardiac injury.  
Kidney biopsies of patients with acute renal failure following CPB demonstrate a 
substantial degree of apoptosis.  TNF induces renal injury by direct and indirect 
mechanisms.  TNF directly induces renal apoptosis and reversible dysfunction; however, 
concurrent TNF-induced cardiodepression via apoptosis limiting renal blood flow, further 
provoking a vicious cycle of renal TNF production and injury during CPB, MI, and CF 
[3].  A better understanding of the pathways of apoptosis and their regulation may yield 
novel therapeutic targets for cardiorenal syndrome [2].  Our focus is on the apoptotic 
pathway induced by TNF (see Figure 1).  We looked at pro-apoptotic signaling (active 
forms of caspase 2, 3, 9—Aim 4) and apoptotic markers indicating that apoptosis is 
occurring (cleaved forms of PARP —Aim 2).  As proposed in research Aim 3, our lab 
also looked at which renal cells are undergoing apoptosis in response to cardiac ischemia 
by performing immunohistochemistry using the specific antibodies of active caspase 3 
and cleaved PARP. 
2.3 TNF 
The cytokine TNF elicits a wide range of biological responses, including 
inflammation, cell proliferation, differentiation, and apoptosis [24], [25].  Similar to 
growth factors, TNF can act on the same cell that produces it (an autocrine effect); on 
cells in the immediate vicinity (a paracrine effect); or systematically (and endocrine 
effect) [16].  One of the most intriguing actions of TNF is the induction of apoptosis.  
Apoptosis is almost certainly relevant to some of the toxic effects of TNF, such as shock 
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and inflammation.  TNF-induced apoptosis may also have physiologic relevance, for 
example, mediating apoptosis of infected cells to help protect the host or down regulating 
inflammatory cells [26].  Increased serum levels of TNF have been observed with cardiac 
ischemia during CPB and MI [3], [4], [5], [6], and also in patients suffering from CF [7].   
The fact that the myocardium produces as much TNF per gram of tissue as the liver or 
spleen, both which possess large macrophage population, which are major sources of 
TNF, implicates the myocardium to be a potential source of TNF in cardiac disease [3].  
Levine et al. [7] research suggests that TNF plays a role in the progression of myocardial 
disease.  They observed that circulating levels of TNF are increased in patients with 
chronic heart failure and that the patients with elevated circulating levels of TNF had a 
greater impairment of renal function [7].  As already mentioned, elevated serum levels of 
TNF are also observed in patients undergoing CPB and with MIs.  Research on patients 
who underwent CPB showed a strong correlation between the levels of TNF and the 
duration of cardiac ischemia during CPB [5].   
TNF is produced and released by both the heart and kidney [3].   It was once 
thought that TNF released by the kidney was via the secretory product of local 
macrophages but through further investigation it was discovered that the renal glomerular 
mesangial cells produce their own TNF in response to ischemia, exogenous TNF, and IL-
1 [25].  Of all the inflammatory mediators, TNF appears to be one of the most potent in 
terms of its ability to induce cardiorenal syndrome via direct cytoxicity and apoptosis [3].   
TNF is proposed to initiate destruction in the kidney through several avenues.  
TNF stimulates the production of reactive oxygen species from mesangial cells as well as 
recruitment of neutrophils and monocytes to the kidney enhancing their adhesion to 
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glomerular cells.  TNF also reduces glomerular blood flow and glomerular filtration rate 
by stimulating renal mesangial cells to produce a variety of vasoconstrictive (platelet 
activating factor, endothelin-1, prostaglandins such as Thromboxane A2) and vasodilatory  
(adenosine, nitric oxide, prostaglandins such as Prostaglandin E2) mediators [3],  [27].     
Thus, TNF promotes renal dysfunction via direct cytotoxicity, vasoconstriction, 
decreased renal blood flow, the recruitment of neutrophils and monocytes, increased 
albumin permeability and, glomerular fibrin deposition [3], [27].  TNF has also been 
implicated in a variety of inflammatory diseases of the kidney, including autoimmune 
lupus nephritis, glomerulonephritis, diabetic nephropathy and septic acute renal failure 
[25].   As indicated by research, TNF can be extremely damaging to the kidney. 
 TNF exists as a cellular membrane bound precursor form and is processed to a 
soluble, secreted form.  This processing of the TNF precursor is required for TNF 
secretion [28].  TNF exists as a 26 kilodalton (kD) cell membrane bound associated form 
and a 17 kD soluble form.  The 17 kD TNF is released as a result of proteolytic cleavage 
within the cell membrane, of the 26 kD form by TNF converting enzyme (a membrane-
anchored zinc protease, TACE), a member of the matrix metalloproteinase (MMP) family 
[29], [30], [31]. 
 Many proteins such as TNF exist in both membrane-bound and soluble forms as a 
result of post-translational proteolytic processing [32].  The process of membrane 
proteins being released by proteolytic cleavage is referred to as ectodomain shedding.  An 
appropriate balance between membrane-bound and soluble forms of proteins such as 
TNF appear to be important for their normal physiological role [33], [32].   Under 
physiologic conditions, the 26 kD precursor proTNF, a type II transmembrane protein, is 
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proteolytically cleaved by TACE.  TACE is a multi-domain, type I transmembrane 
protein that includes three domains: pro, catalytic, and hemopexin.  The pro region 
contains a cysteine switch, a feature that maintains the enzyme in an inactive state.  The 
pro domain can be autocatalytically removed to become active.  The catalytic domain 
contains a standard zinc ligand binding motif and the hemopexin domain, which is 
important for the recognition of membrane bound TNF [28], [33].   For the most part, 
TACE is constitutively expressed and becomes activated by intracellular kinase cascades 
upon stimulation of a cell [34].  Research has shown TACE to be highly selective for 
TNF [35]. 
  The TNF receptor is referred to as the “death receptor” [21].  TNF can bind with 
two different receptors named TNF-R1 (55kDa) and TNF-R2 (75kDa) [21], [26], [3], 
[24], [27],  [2], but it appears TNF-R1 is more potent than TNF-R2 [26].   In most cells 
TNF-induced effects are mediated by TNF-R1, and TNF-R1 is responsible for the 
generation of the cytotoxic death signals [21], [26], [3], [24], [27],  [2].    The wide 
repertoire of signaling responses elicited by TNF results from the ability to recruit a range 
of cytosolic adaptor proteins such as TNF receptor-1-associated death domain (TRADD).  
The interaction between TNF-R1 and adaptor proteins is dependent on homologous 
regions known as a “death domain.”  Death domains (DD) are so named for their 
essential role in initiating apoptosis.  These domains mediate apoptosis by recruitment of 
other proteins such as Fas-associated death domain (FADD) and receptor interacting 
protein (RIP)-associated ICH-1 death domain (RAIDD) that additionally contain a “death 
effector domain” (DED), which recruit and activate caspases.    Once TNF binds to TNF-









































A P O P T O S I S 
Figure 1.  TNF-induced apoptosis pathways.  Tumor necrosis factor (TNF) 
binds to and activates the tumor necrosis factor receptor (TNF-R1).  Once the  
receptor is activated it can begin recruitment of several proteins eventually 
leading to apoptosis.  TRADD, TNF receptor-1-associated death domain; 
FADD, Fas-associated death domain; RIP, receptor interacting protein; 
RAIDD, RIP-associated ICH-1 death domain; NF-κB, nuclear factor kappa 
B. 
 
receptor’s DD.  TRADD uses its DD to recruit the FADD protein, which contains both a 
DD and a DED and initiates the pro-apoptotic activity of TNF by engaging caspase 8 (a 
proteolytic enzyme explained later) through its corresponding DED thereby initiating 
apoptosis [21] , [3], [24], [36], [27], [26].  TRADD can also recruit receptor interacting 
protein, which contains a DD that engages the DD of RAIDD, RAIDD in turn recruits 
and activates caspase 2.  Caspase 2 can play two roles; one that can trigger direct 
apoptosis much like caspase 3, and one that can activate caspase 3 thereby causing 
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apoptosis.   Furthermore, RIP can activate nuclear factor kappa B (NF-κB), which is a 
transcription factor that enters the nucleus and binds to specific promoter regions of 
target genes [37], [38], [39] (Figure 1).  
The activation of NFκB can increase anti- or proapoptotic signaling, increase the 
levels of TNF, and increase inflammation.  In most cells, NFκB exists in a latent state 
bound to its inhibitory proteins collectively called inhibitory κB (IκB) that masks the 
NFκB nuclear localization site.  Following activation, phosphorylation of IκB results in 
disruption of the NFκB-IκB complex and degradation of IκB.  Once liberated from IκB, 
NFκB translocates from the cytoplasm to the nucleus where it docks to DNA at one of 
four NFκB binding sites such as the TNF promoter region.  It has been demonstrated that 
at least two of these TNF promoter regions must be bound by NFκB for TNF 
transcription to occur [3].   
 NFκB consists of two major polypeptides, p50 and p65.  Both p50 and p65 
homodimers and p50/p65 heterodimers bind to DNA.  p65 is required for binding of the 
IκB inhibitor and activates transcription.  p50, however does not activate transcription.  It 
has been shown the both p50/p50 homodimers and p50/p65 heterodimers bound NFκB to 
the p53 promoter (p53 suppressor protein discussed later).  So likewise, TNF induces 
NFκB activity and activates the p53 promoter.  Studies showed that TNF, a specific 
NFκB inducer, also had an inducible effect on the p53 promotor, and activation of both 
required an intact NFκB site.  Since NFκB is activated by signals that pose a threat to the 
survival of cells and p53 arrests cells in G1 phase of the cell cycle, NFκB induction of 
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p53 may be a mechanism to arrest cell cycle progression and allow recovery from 
damage [40].   
As illustrated (Figure 1), TNF can also initiate apoptosis through mitochondrial 
amplification by cleaving Bid (a protein of the Bcl-2 family explained later) or by 
increasing the levels of Bax (another protein of the Bcl-2 family via p53) implicating 
other pathways in which TNF can evoke cell injury.  This mitochondrial amplification 
can be measured by increased levels of caspase 9 (mechanism explained later). 
 As described, stimulation of TNF-R1 can simultaneously activate several 
signaling pathways within the cell leading to apoptosis, but interestingly the stimulated 
TNF-R can also lead other pathways that can counter the death signals and result in cell 
survival.  The balance of these two systems determines if the cell lives or dies. Most of 
the signaling that causes cell death via TNF has been explained and is shown in Figure 1.  
Several antiapoptotic mechanisms appear to begin with the protein RIP.  Although RIP 
initiates the activation of caspase 2, which can cause apoptosis, it can also play a role in 
cell survival by interacting with IκB, there by activating NF-κB, and TNF-receptor 
associating factor  (TRAF) [24], [41].   
TRAF2 is characterized by the presents of an N-terminal ring and zinc finger 
containing domain, and a C-terminal TRAF domain.  There has been six related TRAF 
proteins found but only TRAF1 and TRAF2 have been shown to be involved in TNF 
signaling.  TRAF along with RIP can activate NF-κB, which in turn translocates into the 
nucleus and promotes the expression of antiapoptotic proteins such as cellular inhibitor of 
apoptosis (cIAP), TRAF1, and A20.  Interestingly, a number of the NF-κB-dependent 
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expressed antiapoptotic proteins bind directly to TRAF2 leading to their recruitment to 
the TNF-R complex [24].   
cIAP1 and cIAP2 are the only members of IAP family that can interact with 
TRAF2 [24].  cIAP works by preventing hydrolysis of caspases by sterically hindering 
access to the catalytic center of the protease [42].  IAPS has shown to directly bind and 
inhibit caspases 3, 7, and 9 [43].  A20 is an inducible cytoplasmic zinc finger protein that 
interacts via the N-terminal non-zinc finger-containing domain of the TRAF1/TRAF2 
complex.  A20 has a dual effect on TNF-mediated signaling; a potent inhibitor of NF-κB 
activation as well as an inhibitor of cell death.  In most cells, basal expression levels of 
cIAPs, TRAF1, and A20 are very low or even undetectable, however, they are strongly 
upregulated in an NF-κB-dependent manner upon the stimulation of cells by TNF [24]. 
Yet another delicate balance between cell life or death stimulated by TNF is with 
the ceramide pathways. Sphingomyelin initiates an evolutionarily conserved and 
ubiquitous intracellular signaling pathway.  As a major phospholipid, sphingomyelin is 
largely confined to the outer leaflet of cellular membranes and is hydrolyzed by 
sphingomyelinases (SMase, sphingomyelin-specific type C phospholipases) into 
phosphocholine and ceramide.  The phosphocholine head group is released into the 
aqueous environment while ceramide diffuses within membranes, acting as an 
intracellular messenger.  Inducible SMase activity in intact cells was initially described in 
response to diacylglycerols (DAG).  Transient accumulation of ceramides derived from 
sphingomyelin hydrolysis was later recognized as a component of the signaling events 
that originate from different cell-surface receptors, including TNF-R1.  A growing 
number of cell-surface receptors are now being shown to generate signals that trigger the 
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hydrolysis of sphingomyelin to release diffusible ceramides.  Ceramides have been 
implicated as key mediators in signaling pathways, with outcomes as diverse as cell 
proliferation, differentiation, growth arrest and apoptosis.  The response depends on the 
cell type, whether the signal is integrated with other signals originating from the same 
receptor or on the subcellular location of sphingomyelin hydrolysis and ceramide release 
[44].   
 Ceramide produced by SMases has been recognized as an important 
second messenger.  By binding to its receptor, TNF rapidly activates two distinct types of 
SMase, a membrane-associated neutral (N)-SMase, and an endosomal acidic (A)-SMase.  
N-SMase and A-SMase are activated independently by different cytoplasmic domains of 
TNF-R  [45], [41].  The activation of these two SMases through TNF-R is mediated by 
different adapter proteins that interact with separate cytoplasmic domains (Figure 2).  The 
DD-associated proteins TRADD and FADD mediate A-SMase activation, and the 
activation of N-SMase is mediated by the novel protein factor associated with N-SMase 
activation (FAN) that binds to a specific binding site, N-SMase activation domain (NSD), 
located upstream of the TNF-R DD.  Binding to the TNF-R seems to be required for the 
function of FAN.  Each type of SMase specifically couples to select pathways of TNF 
signaling (Figure 2).  Ceramide generated by N-SMase directs the activation of protein 
kinases and phospholipase A2.  In contrast, A-SMase triggers the activation of NF-κB.  
No apparent cross talk has been detected between N-SMase and A-SMase pathways, 
indicating that ceramide action depends on the topology of its production [45].  As can be 
seen in Figure 2 there are many ceramide pathways stimulated by the activation of the 











































































Figure 2.   TNF stimulation of ceramide leading to inflammation, cell 
survival, or cell death.  TNF activates two types of SMase 
(sphingomyelinases), membrane-associated neutral (N)-SMase, and an 
endosomal acidic (A)-SMase, mediated by different adapter proteins.   The 
ceramide produce by Smases has been shown to be an important second 
messenger and a key mediator in signaling pathways that can lead to cell 
proliferation, differentiation, growth arrest, and apoptosis. 
 
necessary to point out for the full ramification of the TNF-R in both cell death and cell 
survival. 
Research to increase the understanding of the death receptor’s pathways may give 
insight to both cardiac and renal dysfunction opening new therapeutic avenues to prevent  
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cardiorenal syndrome.  We investigated the apoptotic pathway of TNF by looking at 
levels of the active forms of caspase 2, caspase 3, and caspase 9 (Aim #4a).  Because 
caspase 9 is a direct result of mitochondrial disruption, we used it as a marker for 
mitochondrial apoptosis amplification.  To insure that TNF is in fact one of the major 
players in  cardiorenal  syndrome  we inhibited its action  by inhibiting the conversion of 
the proTNF to its soluble form preventing the secretion of TNF (Aim 4b).  Also we 
determined which renal cells types express apoptotic signaling due to cardiac ischemia 
through immunohistochemistry (Aim #3).  
2.4 Caspases 
Caspases are a family of proteases, which are essential molecules in pro-apoptotic 
pathways that are initiated in response to death stimuli such as TNF [20], [2], [24].  
Caspases (cysteinyl aspartate-specific proteases) mediate highly specific proteolytic 
cleavage events in dying cells, which collectively initiate apoptosis.  It appears that the 
role of these proteases in cell suicide is to disable critical homeostatic and repair 
processes, as well as to cleave key structural components resulting in the systematic and 
orderly disassembly of a cell.  Caspases have been found in organisms ranging from the 
nematode Caenorhabditis elegans to humans.  The 13 identified mammalian caspases 
(named caspase 1 to caspase 13) have distinct roles in apoptosis and inflammation.  The 
family includes two murine homologs (11 and 12) that have no human counterparts.  In 
apoptosis, caspases are directly responsible for proteolytic cleavages that lead to cell 
disassembly (effectors—caspases 2, 3, 6, 7) and are also involved in upstream regulatory 
events (initiators—caspases 2, 8, 9, 10) with other caspases (1, 4, 5) playing a role in 
inflammation [23], [20], [46]. 
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Early observations of apoptosis found common morphological changes occurring 
in tissues and species, which led to the suggestion that this process is governed by a 
conserved biochemical system.  It is now clear that these changes are due to the activities 
of a common set of effector caspases.  The observation that distinct death signals result in 
the same manifestations of apoptosis is explained by the finding that effector caspases are 
activated by different initiator caspases, each of which is activated by a set of 
proapoptotic signals.  Available evidence suggests that caspases are regulated by the 
opposing effects of activators and inhibitors.  A signal apparently initiates three pathways 
involving cofactors, initiator caspases, and inhibitors.  Activation of cofactor (for 
example, cytochrome c relocation from mitochondria to cytoplasm), modification of the 
caspase (for example, relocation of caspase 8 to a receptor complex), and inactivation of 
inhibitors together result in activation of the initiator caspase [23]. 
All apoptotic caspases are constitutively expressed and exist inactive in normal 
cells.  Most of these proteases are synthesized as precursors that have little, if any, 
catalytic activity.  The precursor is usually converted to the active enzyme by proteolytic 
processing mediated either by another protease or by autocatalysis, triggered by the 
binding of cofactors or removal of inhibitors.  Hence, large amounts of a precursor can be 
accumulated in advance and activated on demand [23], [47].  Unlike most other 
postranslational modifications, proteolysis is irreversible.  This implies that regulation of 
caspases is limited to control of their activity and availability of substrate since the only 
known way of correcting a cleaved protein is to make it again [23].  
Two features of the proenzyme structure of caspases are central to the mechanism 
of activation of these enzymes.  First, the NH2-terminal domain, which is highly variable 
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in sequence and length, is involved in regulation of activation.  Second, all domains are 
derived from proenzyme by cleavage at caspase consensus sites, implying that these 
enzymes can be activated either autocatalytically or in a cascade of enzymes with similar 
specificity.  Caspases are among the most specific of proteases, with an unusual and 
absolute requirement for cleavage after aspartic acid.  Recognition of at lease four amino 
acids at the NH2-terminal to the cleavage site is also a necessary requirement of efficient 
catalysis.  The strict specificity of caspases is consistent with the observation that 
apoptosis is not accompanied by indiscriminate protein digestion; rather, a select set of 
proteins is cleaved in a coordinated manner, usually as a single site, resulting in loss or 
change in function [23]. 
Caspases can regulate their own activation achieved through positive and negative 
feedbacks, one of which is amplification loop.  In this case, the active protease can 
directly or indirectly activate its own precursor, resulting in an exponential rate of 
activation and ensuring that the caspase can be fully activated quickly.  A large body of 
genetic and biochemical evidence supports a cascade model for effector caspase 
activation:  a proapoptotic signal culminates in activation of an initiator caspase, which, 
in turn, activates effector caspases, resulting in cellular disassembly. Different initiator 
caspases mediate distinct sets of signals.  For example, caspase 8 is associated with 
apoptosis involving death receptors, and in contrast, caspase 9 is involved in death 
induced by cytotoxic agents [23]. 
Activation of initiator caspases requires binding to specific cofactors, a 
mechanism commonly observed with proteases.  This binding is triggered by a 
proapoptotic signal mediated through one of at least two distinct caspase prodomains and 
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its corresponding cofactor.  Activation of procaspase 8 requires association with its 
cofactor FADD, while procaspase 9 activation involves a complex with the cofactor 
Apaf-1 along with cytochrome c, indicating that caspase activation may require multiple 
cofactors [23], [20], [24], [22]. 
Initial activation of caspases can involve transduction of a signal from membrane 
receptors belonging the TNF receptor family, such as TNF-R1.  Stimulation of death 
receptors results in activation of caspase 8, which goes on to activate the effector 
caspases 3, 6, and 7, with caspase 3 being a key effector protein of the apoptotic 
machinery [2], [22], [48], [20], [22], [2].  The activation of caspase 8 can also trigger 
downstream caspases indirectly by causing the mitochondria to release cytochrome c.  
Procaspase 8 contains two tandem repeats of the DED within its N-terminal prodomain, 
which is involved in the recruitment of procaspase 8 to the TNF-R/FADD complex by a 
homotypic interaction with the DED of FADD.  Binding to FADD leads to procaspase 8 
oligomerization and its autoproteolytic activation, which will eventually lead to cell death 
[24] via two pathways:  activation of downstream effector caspases or activation of Bid 
ultimately causing mitochondrial apoptotic amplification [22], [48], [20], [22], [2]. 
Multiple stimuli such as Bax, Bid, oxidants, calcium overload, active caspases, 
and ceramide can trigger mitochondria to release caspase-activating proteins, among 
which are cytochrome c and apoptosis-inducing factor (AIF).  Two general mechanisms 
of release of caspase-activating proteins from mitochondria have been proposed:  one 
involves osmotic disequilibrium leading to an expansion of the matrix space, organellar 
swell, with subsequent rupture of the outer membrane; the other consist of opening 
channels in the outer membrane (without organellar swelling), thus releasing cytochrome 
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c from the intermembrane space of mitochondria into the cytosol.  Cytochrome c 
activates caspases by binding to the cytosolic protein of Apaf-1, inducing it to associate 
with procaspase 9 (this complex is often referred to as an apoptosome), thereby triggering 
caspase 9 activation and initiating the proteolytic cascade that culminates in apoptosis by 
the activation of caspase 3 [49], [20], [50], [2]. 
Activation of effector caspases such as caspase 3, produce the net effect of halting 
cell-cycle progression, disabling hemeostatic and repair mechanisms, initiating the 
detachment of the cell from its surrounding tissue structures, disassembling of structural 
components, and marking the dying cell for engulfment by other cells such as 
macrophages [47].  As mentioned before, this cascade of events is irreversible.  Apoptotic 
inhibitors are not protected against this cell death cascade, and can possibly be a 
contributor.  Caspases can cleave Bcl-2 proteins (many of which are apoptosis inhibitors), 
and it appears that cleavage cannot only inactivate these proteins, but also produces 
fragments that promote apoptosis [23].   Activation of caspase 3 in the mammalian cell 
has been linked to the proteolytic cleavage of cellular substrates including PARP 
(explained later).   
Caspase 2 can be activated as well by the TNF receptor (Figure 1) via the 
TRADD, RIP, RAIDD pathway.  Interestingly, caspase 2 can play two roles:  one is by 
acting like an effector caspase and causing apoptosis directly, another is by acting as an 
initiator caspase much like caspase-8 thereby activating effector caspases like caspase-3, 
which initiates apoptosis directly [23], [20], [23], [37], [38], [39], or by cleaving and 
activating Bid thus stimulating mitochondrial apoptosis application.  It has been 
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demonstrated recently that caspase 2 can induce the release of cytochrome c independent 
of Bid or other cytosolic factors [51].  
As stated briefly above, caspases 1, 4, and 5 predominantly play a role in 
inflammation.  Caspase 1, for example, cleaves proIL-1β generating the mature, 
biologically active form of this cytokine.  As a consequence, this enzyme has been the 
subject of intense investigation as an attractive target for the treatment of IL-1-driven 
inflammatory diseases.  Caspase 1 is synthesized as a dormant 45kD proenzyme that 
resides in the cell cytoplasm, and is proteolytically activated in response to various 
inflammatory challenges.  Studies show that caspase 1 deficient mice cannot generate 
mature IL-1β and found these animals to be resistant to lipopolysaccharide (LPS)-
induced endotoxic shock [47].  Although the caspases involved with inflammation alone 
are interesting, and in need of researching, the caspases of interest in this research are 
those involved in apoptosis induced by TNF:  caspase 3, caspase 2, and caspase 9 (Aim 
#4). 
A survey of caspases and or of their substrates suggests that caspases participate 
in apoptosis in a manner reminiscent of a well-planned and executed military operation.  
They cut off contacts with surrounding cells, reorganize the cytoskeleton, shut down 
DNA, disrupt the nuclear structure, induce the cell to display signals that mark it for 
phagocytosis, and disintegrate the cell into apoptotic bodies [23].   If there is an 
imbalance of cell apoptotic inhibitors verses proapoptotic caspases, once the caspase 
cascade is initiated the cell is doomed.  Our studies looked at the active forms of caspase 
2, 3, and 9 (Aim #4a.) because these are the caspases that indicate the activation of TNF-
R pathways. 
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2.5 Bcl-Family Proteins 
There is a distinct genetic pathway apparently shared by all multicellular 
organisms that can either initiate or prevent apoptosis.  The Bcl-2 family of proteins 
constitutes a decisional checkpoint within the apoptotic pathway.  Full members of the 
Bcl-2 family share homology in four conserved domains designated BH1, BH2, BH3, 
and BH4 [46], [22].   Bcl-2 family proteins consist of both anti-apoptotic (Bcl-2 or Bcl-
xL) and pro-apoptotic proteins (Bax, Bak, Bad, and Bid), which can regulate caspase 
activation mainly at the mitochondria level [22], [46], [48] signified by the release of 
cytochrome c, changes in the transmembrane potential, and mitochondrial permeability 
[48].   Many, but not all, Bcl-2 family proteins reside in the mitochondrial outer 
membrane anchored by a hydrophobic stretch of amino acids located within their COOH-
terminal with the proteins oriented toward the cytosol.  One clue to how the Bcl-protein 
family exerts their mitochondrial effects has come from determination of the three-
dimensional structure of the Bcl-xL protein.  The Bcl-xL protein is composed of seven α 
helices joined by flexible loops and shares striking similarity to the pore-forming 
domains of some types of bacterial toxins such as the diphtheria toxin.  These toxins are 
known to insert into lipid bilayers and form channels capable of conducting ions.  As 
predicted by their structures, Bcl-2, Bcl-xL, and Bax can form ion channels when they 
are added to synthetic membranes.  The Bcl-xL was shown to form a cation-specific 
channel in both vesicles and planar lipid bilayer, whereas Bax, the pro-apoptotic counter 
part formed an anion-selective channel.  Therefore, relative ratios of pro and 
antiapoptotic proteins could influence the flow of ions and, subsequently, the flow of 
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water causing the swelling and rupture of the mitochondrial membrane resulting in the 
release of cytochrome c [49], [20]..   
 The Bcl-2 protein family regulates a variety of mitochondrial events.  Bcl-2 and 
Bcl-xL can inhibit not only caspase-dependent apoptosis but also oxidant and hypoxia 
induced necrosis.  On the other hand, Bax, Bak, Bad, and Bid can induce cytochrome c 
release and cell death.  The Bax induced release of cytochrome c release can be inhibited 
by Bcl-2 and Bcl-xL [49].  The balance in expression between Bcl-2 and Bax has been 
suggested as a major role in the pathway of apoptotic cell death.  The downregulation of 
Bcl-2 and upregulated Bax proteins have been observed in ischemic heart or kidney 
tissue [52].  As mentioned above, the expression of Bax can be directed by TNF via 
simulation of NFκB by way of p53 suppressor protein [40] (Figure 1). 
 Interestingly, Bid is a BH3-only member of the Bcl-2 family of proteins and a 
substrate of caspase 8 activated by the TNF-R1 pathway (Figure 1).  Bid lacks the 
COOH-terminal membrane anchoring domain and therefore is in the cytosol of cells as 
an inactive precursor [22].  Thus, Bid connects the death receptor to the mitochondria 
apoptosis pathway, and is responsible for the mitochondrial release of cytochrome c 
which complex with Apaf-1 and procaspase 9 subsequently activating caspase 3 (Figure 
1) [48], [36],[46].    
The cytosolic 22 kD Bid represents its inactive form that is proteolytically cleave 
by caspase 8 to generate the active 15 kD form of Bid [46] .  The 15 kD form is often call 
the truncated Bid (tBid).  The 15 kD conformation rather selectively targets the 
mitochondria where it resides as an integral membrane protein responsible for the release 
of cytochrome c.  The rapid movement of tBid from the cytosol to mitochondrial 
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membranes suggest a specific mechanism of targeting.  tBid by itself is sufficient to 
induce complete release of cytochrome c from the mitochondria.  Bid is a much more 
potent cytochrome c releasing factor than Bax, another key cytochrome c releasing 
protein.  Studies showed Bax only released up to 20% of the total mitochondrial 
cytochrome c even at a high concentration, whereas, Bid was able to release close to 
100% of mitochondrial cytochrome c at a 500-fold lower concentration.  It is not clearly 
understood how Bid impacts the mitochondria but it has been observed that Bid initiates 
the release of cytochrome c without evoking gross mitochondrial swelling and 
permeability transition; the two events that have been proposed to cause cytochrome c 
release.  Bid appears to be a potent connection between the death receptor, and once 
more, another avenue for initiating apoptosis [22].  
 Fascinatingly, it has been reported that Bcl-2 and Bcl-xL, usually protective of 
the mitochondria, can be converted by activated caspases from anti- to pro-apoptotic 
molecules.  Thus, caspase cleavage can upset the balance of the anti-apoptotic Bcl-2 
members allowing for a feed forward loop to ensure cell death [46].   
2.6 p53 
The p53 suppressor protein is considered the guardian of a cell.  It arrests the cell 
cycle allowing time for cell repairs.  However, if there is too much cell damage and the 
repair process fails, p53 can accumulate and stimulate apoptosis [53].  Studies have 
revealed elevated levels of p53 in cardiac disease along with an increased incidence of 
apoptosis.  It has also been shown that expression of p53 alone is sufficient to trigger 
apoptosis of ventricular myocytes [54].  Preliminary studies done in our lab show 
increased levels of p53 in the kidney after induced coronary ischemia and TNF infusion.   
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Together, these studies support a key role for p53 in cardiorenal syndrome.   Donato et al. 
has published their data results demonstrating an increase in p53 levels after cells (ME-
180S—apoptotic sensitive cell line) were exposed to TNF [55] in much the same pattern 
as our findings.  Research has shown that NF-κB, a transcription factor activated by TNF, 
binds and activates the p53 promotor thus increasing p53 protein levels in a cell 
stimulated by TNF [40].  Once again, this indicates another route in which the cytokine 
TNF can induce apoptosis. 
p53 is known to regulate transcription of a number of genes including the pro-
apoptotic Bcl-2 family member Bax.  However, recent evidence suggests that p53 may 
induce apoptosis through a mechanism independent of its gene activating properties.  It 
has been reported p53 mediates apoptosis involving the disturbance of mitochondria, 
which includes the loss of membrane potential, release of cytochrome c, and increased 
caspase 3 like activity consistent with the mitochondrial death pathway.  Although this 
resembles activity of Bax, increased levels of p53 initiated this pathway in the absence of 
Bax expression.  There has been evidence supporting the ability of p53 to induce 
apoptosis by localizing to mitochondria in response to death signals (such as that seen 
with the TNF death receptor) and amplifying transcriptional dependent events [54].   
High levels of p53 can indicate extreme cell stress caused by cytotoxins such as TNF and 
subsequent apoptosis due the stress [55].   
2.7 PARP 
PARP is a nuclear DNA-binding enzyme that detects DNA strand breaks and then 
functions in excision repair of damaged DNA.  It has three functional domains, and N-
terminal DNA binding domain (DBD), a C-terminal catalytic domain, and an 
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automodification domain in the middle of the protein.  DBD of PARP contains two zinc 
fingers that actively binds to DNA strand interruptions.  Activated PARP catalyzes the 
formation of long and branched polymers of adenosine diphosphate (ADP)-ribose using 
nicotinamide-adenine dinucleotide (NAD) as a substrate.  It has been reported that at a 
very early stage of apoptotic cell death, while the cell continues to retain membrane 
integrity and the majority of the proteins are not degraded, PARP (an approximate 116 
kD protein) is specifically cleaved to form two fragments of molecular mass, 89 and 24 
kD (Figure 3).  Cleavage of PARP has been found to be a sensitive parameter of 
apoptosis and can be detected within 15 minutes [56].   The cleaved forms of PARP has 
become the research hallmark for indicating apoptosis [20], [50], [2], [49], [56].   
Since PARP is activated by DNA damage, it is suggested that DNA degradation 
occurring during cell death would result in massive activation of PARP.  Once cleaved by 
caspase 3, PARP can then become a contributor to apoptosis through two possible 
methods.  One by the 89 kD fragment, which if left relatively unaltered would permit 
unchecked syntheses of poly(ADP-ribose) rapidly consuming the cell of NAD and ATP 
(Figure 3).  Secondly, the 24 kD fragment could block DNA repair at the strand breaks.  
This PARP fragment with its zinc fingers binds to DNA at strand breaks, and without the 
catalytic repair activity of the 89 kD fragment, the 24 kD fragment remains bound, 
thereby, freezing the DNA.  Since PARP is present in large abundance, and nearly all of 
the PARP is stably cleaved by caspase 3 to form the 24 and 89 kD fragments, there could 
be a few million molecules of the 24 kD fragment in the nucleus of an apoptotic cell.   
Thus, the 24 kD fragment could contribute to cell death by blocking DNA repair at the 
strand breaks.  These cleaved forms of PARP have become the research hallmark for 
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indicating apoptosis [20], [50], [2], [49], [56] .  To show apoptosis is occurring in this 
study, we looked at the levels of cleaved product of PARP (Aim #2). We also looked 
histologically to establish which cell types where undergoing apoptosis by probing 






































Figure 3. PARP contribution to apoptosis.  Once caspase 3 is activated it can 
enter the nucleus of the cell and cleave PARP (poly ADP-ribose 
polymerase), an enzyme used to detect and repair DNA.  Once PARP is 
cleaved it is rendered nonfunctional and can become part of the mechanism 
resulting in apoptosis through both segments created by caspase 3:  24 kD 
fragment can stick to and block DNA repair and 89 kD fragment can deplete 





 The purpose of these studies is to acquire a clearer understanding of cardiorenal 
syndrome.  Observations have been made showing a small percentage of patients suffer 
acute renal failure after undergoing cardiopulmonary bypass as well as patients in cardiac 
failure.  The same clinicians and researchers making these observations think the cause of 
the renal injury are cytokines released by the injured or ischemic myocardium, but there 
has been no research done to support or disprove this theory [3], [4], [5], [6].  Because 
TNF-α is suspected to be the most potent cytokine released from the myocardium and the 
most likely to induce renal dysfunction [3], it is the focus of this study. 
 My hypothesis is renal injury, as indicated by apoptosis in the kidney, results 
from the production and release of cytokines due to cardiac ischemia.  The way in which 
I plan to address my hypothesis is through the specific aims of this research:  (1) illustrate 
there is an increase in serum TNF-α after cardiac ischemia in our cardiac ischemic model 
as seen in other studies;   (2) find if there is injury to the kidney, measured by apoptosis 
(cleaved PARP), due to coronary occlusion, (3) locate the renal cells being injured by 
cardiac ischemia, and (4) measure renal apoptotic signaling (caspases 2, 3, and 9) after 
cardiac ischemia and examine the role of TNF-α in these activities.  We used the 
following described procedures to investigate these specific aims. 
3.2 Animals 
Adult male Sprague-Dawley rats were obtained from the Oklahoma State 
University College of Osteopathic Medicine animal facility or purchased from Charles 
 30
River Company.  Animals were housed in a separate room in the animal facility in plastic 
bins with adequate bedding, and maintained on standard rat chow and tap water.  Animal 
facilities were under the direction of full-time animal caretakers, and the Oklahoma State 
University College of Osteopathic Medicine animal Use Committee approved this 
project.  The college of Osteopathic Medicine complies with the NIH policy of animal 
welfare of the Animal Welfare Act and all other applicable laws. 
3.3 Induced Myocardial Ischemia 
Animals were first anesthetized with isofluorane/oxygen (2% volume/volume) at 
2-liters per minute followed by an intraperitoneal (i.p.) injection of ketamine HCl (100 
mg/kg body weight) and xylazine HCl (10 mg/kg body weight).  Catheters were placed in 
the external jugular vein for intravenous injections of medications if necessary, and the 
carotid artery for monitoring the animals mean arterial pressures measured by a 
computerized blood pressure transducer.  A tracheotomy was performed with the animal 
being placed on mechanical ventilation with a volume-cycled respirator.   To perform 
coronary artery occlusion the animals’ chest were opened via left thoracotomy, the 
pericardium was cut away, and the interventricular coronary artery was occluded using a 
silk suture.   At the end of 15 minutes of coronary ischemia, trypan blue dye was injected 
into the coronary artery in order to identify the degree and the regions of myocardial 
ischemia.  Once ischemia was determined the kidneys were harvested, rinsed in chilled 
normal saline and either rapidly frozen in liquid nitrogen and stored at -80°C to be further 
processed fromy Western blot analysis, or placed in buffered fixative for 
immunohistochemistry.    We followed the same procedures for the control animals 
except there was no occlusion of the coronary artery. 
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3.4 Infused TNF-α 
Again animals were anesthetized first with isofluorane/oxygen (2% 
volume/volume) at 2-liters per minute  followed by an i.p. injection of ketamine HCl (100 
mg/kg body weight) and xylazine HCl (10 mg/kg body weight).  Catheters were placed in 
the external jugular vein for intravenous injections of medications if necessary, and the 
carotid artery for monitoring the animals mean arterial pressures.  A tracheotomy was 
performed without the animal being placed on mechanical ventilation because animal did 
not need ventilation assistance since the chest was not opened to perform coronary 
ligation.   2ng of TNF (Sigma-Aldrich Inc., St. Louis, MO) per 1ml of extracellular fluid 
was diluted in 2 mls of normal saline and intravenously injected via the external jugular 
catheter for a period of 15 minutes.  Immediately after the TNF infusion the kidneys were 
harvested, rinsed in normal saline, and either rapidly frozen in liquid nitrogen, and stored 
at -80°C for Western blot analysis or placed in buffered fixative for 
immunohistochemistry.  We followed the same procedures for the control animals except 
we infused normal saline only. 
3.5 Immunohistochemistry 
Kidney tissue was fixed in buffered formalin for 12 to 18 hours, dehydrated in 
ascending series of ethanol concentrations (75%, 95%, 100%) and xylene, and then 
embedded in paraffin wax.  Seven-micrometer sections were dewaxed in xylene and 
rehydrated through a descending series of ethanol concentrations (100%, 95%, 75%).  
Sections were then washed in deionized water before the labeling procedure.  
Endogenous peroxidase was blocked by placing sections in 0.3% peroxide diluted with 
methanol for 30 minutes and rinsed with phosphate buffered saline (PBS).  Nonspecific 
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antibody binding was blocked by incubating sections for one hour in 2% normal blocking 
serum diluted in PBS (1:50 dilution).  Sections were then incubated in primary antibody 
(active caspase 3 or cleaved PARP, Promega, Madison, WI) diluted in PBS (1:100) for 
30 minutes to one hour at room temperature.  After sections were rinsed of primary 
antibody with PBS, secondary antibody was applied to sections diluted in PBS and 
blocking serum incubating for 30 minutes.  The sections were then stained using ABC-
peroxidase substrate kit (Vectastain elite, Vector Laboratories, Burlingame, CA) and 
rinsed.  3,3′-diaminobenzidine tetrahydrochloride (DAB, Vector Laboratories, 
Burlingame, CA) was applied to the sections and allowed to incubate for 15 minutes or 
until desired stain intensity developed.  The sections were rinsed with PBS, dehydrated in 
graded alcohols (75%, 95%, 100%), counterstained with hematoxylin (for visualization), 
and coverslipped. 
3.6 Western Blot Analysis 
 Kidney tissue (stored at –80°C) was pulverized into a powder using liquid 
nitrogen and placed in a 50 milliliter tube containing lysis buffer  (50mM Tris [pH 7.4], 
2% Triton-X, 1M NaCl, 5 mM EDTA, 15% glycerol, and 1mM NaF) with protease 
inhibitors (PI) added (10 µg/ml aprotinin, 20 µg/ml leupeptin, 10 µg/ml trypsin type II-O, 
10 µg/ml trypsin type II-S, and 10 µg/ml pepstatin, Sigma, St. Louis, MO).  Tissue was 
then homogenized and dounced.  Tissue was allowed to incubate in the lysis buffer for 
two hours on ice to ensure all cell membranes where adequately lysed before centrifuging 
(10,000 x g) for one hour to eliminate all large particles.  Supernatant from centrifuged 
samples were decanted and place in appropriately labeled tubes.  Protein levels of each 
sample were determined by Bradford protein assay.  Protein standard curve was analyzed 
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by version 3.O GraphPad Prism.  Proteins were resolved by 4-15% precast SDS 
polyacrylamide gel (Bio-Rad Laboratories, Chicago, IL) electrophoreses.  After 
electrophoreses, samples were transferred to PVDF membranes (Bio-Rad Laboratories, 
Hercules, CA) and membranes were allowed to dry.  Blots were then incubated with 
primary antibody blocked with 5% skimmed milk mixed in tris-buffered saline tween-20 
(TBST) with 0.025% tween-20, for 3 hours to overnight.  The blots were than rinsed with 
TBST and incubated in secondary antibody blocked with 5% skimmed milk mixed in 
TBST with 0.025% Tween 20 for one hour and rinsed with TBST.  After rinsing, the 
blots were developed with the enhanced chemiluminescence (Amersham Biosciences, 
England).  Exposure time to film (Kodak Scientific Imaging film, Fisher Scientific, 
Houston TX) was determined by the degree of signal.  Density of bands of interest from 
exposed film were measure by Bio-Rad G-710 Calibrated Imaging Densitometer. 
3.7 Serum TNF Level Quantification 
 For quantification of serum TNF level a rat TNF specific Ultrasensitive ELISA kit 
(Bio Source International, Camarillo, CA) was utilized.  Pre and post treatment blood 
samples were taken from adult male rats.  The blood sample was allowed to clot for 30 
minutes, after which they were centrifuged (1000 x g) for 10 minutes.  Serum was then 
removed and placed in clean, appropriately labeled tubes and either stored in -4°C or 
immediately tested for TNF levels with the Ultrasensitive TNF ELISA kit.  The ELISA 
assays were strictly preformed as per the ELISA kit’s protocol. 
3.8 TNF Inhibition 
 WTACE2 is a novel metalloproteinase inhibitor specific for TACE, developed 
and donated by Wyeth-Ayerst Research (Pearl River, NJ, USA).  WTACE is a 
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nonpeptide sulfonamide TACE inhibitor bearing a hydorxamic acid as the requisite zinc-
chelating moiety.  This nanomolar level inhibitor contains a novel butynyloxybenzene 
P1′ group, derived from analysis for the TACE x-ray structure, which provides enhanced 
cellular activity.  WTACE2 is an orally bioavailable, broad-spectrum inhibitor of matrix 
metalloproteins (MMPs) [57].  30 minutes prior to experiment male rats were injected i.p. 
with either a dose of 100mg/kg of WTACE2 [57] in a vehicle containing 0.5% 
methocellulose and 2% Tween 80  (Fisher Scientific, Houston, TX) or with just vehicle 
containing 0.5% methocellulose and 2% Tween 80.  After 30 minutes the rat was 
anesthetized and prepped for induced cardiac ischemia or sham control (described 
above). 
3.9 Monitoring Blood Pressure 
 A pressure transducer connected to the carotid artery catheter continuously 
monitored the animals’ blood pressure.    Data was digitized at 500 Hz (Biobench, 
National Instruments) and stored for data analysis. 
3.10 Statistical Analysis 
Statistical analysis is preformed on the data obtained by the Ultrasensitive ELISA.  
Because both blood samples (pre and post treatment) were taken from the same animal, 
this experimental design is considered repeated-measures or pretest-posttest design.  In 
this type of design subjects serve as their own controls, so that the variability owing to 
individual differences is eliminated from the error, thereby increasing the chances of 
observing significant differences between levels of treatment [58], [59].  The statistical 
analysis that was performed was two-way analysis of variance (ANOVA) with repeated 
measures.  P < 0.05 is considered significant. 
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Statistical analysis is also performed on data obtained on mean arterial blood 
pressure (MAP) monitored on each animal for the ischemic, TNF infusion, TNF 
inhibition, and TNF ELISA studies.  The MAP for each animal was monitored 
continuously pre and post assigned treatment.  This experimental design is again 
considered a repeated-measures design, thus two-way ANOVA with repeated measures 
design is used to determine if there is statistical significance of MAP between the 
treatment groups and their controls (P > 0.05).  In addition a one-way ANOVA with 
repeated measures is preformed to assess if there is a any significance between MAP over 
time by comparing all posttest MAPs to the pretest MAP for each animal.  A Dunnett’s 
test is used for comparing the pretest mean to each of the posttest pressures means across 








 It was discovered by Levine et al. [7] in 1990 that patients with chronic heart 
failure had increased circulating levels of TNF.  Serum levels of TNF were elevated 
primarily in the patients with the most advance disease and high levels of TNF identified 
the patients who were the most severely affected by heart failure and the least likely to 
survive. Also in the same study it was found that the patients with elevated circulating 
TNF levels had greater impairment of renal function [7].  More recent clinical 
observations have shown serum levels of TNF are increased after MI and after CPB.  
There were also detections of acute changes in renal function found commonly with 
patients after CPB procedures.  The available data to date indicate that this renal 
dysfunction could be related to myocardial cytokine release that includes TNF [3], [25]. 
 Because TNF is thought to generate a strong relationship between cardiac 
ischemia and renal injury [3], [7], this investigation will look at the TNF levels in order to 
elucidate clues to the role TNF may play in the injury of the kidney due to cardiac 
ischemia, and illustrate there is an increase in serum TNF-α after cardiac ischemia in our 
cardiac ischemic model as seen in other studies (Aim #1).   TNF levels were measured 
before and after 15 minutes of induced cardiac ischemia without reperfusion.  
4.2 Methods 
 
4.2.1 Myocardial Ischemic Model 
 Two groups of six adult, male Sprague Dawley rats weighing between 200 to 350 
grams were used as a control group or a cardiac ischemic group.  Both groups were 
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anesthetized with isoflourane/oxygen (2% volume/volume) at two liters per minute 
followed by an i.p. injection of ketamine HCl (100 mg/kg of body weight) and zylazine 
HCl (10 mg/kg of body weight).  Both groups had catheters placed in the external jugular 
vein for intravenous injections of medication if necessary, and the carotid artery for blood 
draws and monitoring the animals’ arterial pressures.  Both groups had a tracheotomy 
preformed should assisted breathing be required.  For the ischemic group a control blood 
sample was taken before ischemia and a second sample taken 15 minutes after the 
interventricular coronary artery was occluded with a silk suture.  To insure ischemia was 
accomplished, trypan blue dye was injected into the coronary artery to determine the 
ischemic area.  With the control animals, the control blood sample was taken directly 
after the tracheotomy was preformed and the second blood sample (post sample) was 
taken 15 minutes after the control blood sample was drawn. 
4.2.2  Serum Preparation
 Pre and post treatment blood samples were taken off of ice and allowed to clot for 
30 minutes at room temperature.  After 30 minutes each sample was centrifuged 1000 x g 
for 10 minutes.  Serum was then removed and placed in clean, appropriately labeled 
tubes.  Serum samples were stored at –4°C or immediately tested for TNF levels with an 
ultrasensitive TNF ELISA Kit. 
4.2.3  Ultrasensitive TNF ELISA  
 100 µL of each prepared serum sample was place in its designated well of a 96 
well plate of the Ultrasensitive TNF ELISA Kit (Bio Source International, Camarillo, 
CA) along with the TNF standards provided by the kit and prepared according to the kit’s 
protocol.  After completing the ELISA protocol, the wells used in the 96 well plate were 
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read by Dynatech MR 700 microplate reader at the wave length of 450 nm.   Statistical 




 Mean arterial blood pressures were continually monitored for all the animals in 
this study.  Figure 4 shows a graph of the MAP for the two groups (control and 
ischemic).  The graph shows there is a significant difference between the control group 
and the ischemic group at the 14 minute mark, as well as a significant difference in the 14 
minute pressure compared to its control pressure within the ischemic group.  While there 
shows to be a statistical significant difference in these two areas, we feel there is no 
biological significance between these MAP and were confident that animal blood 
pressures remained in a range where organs were properly perfused through out the 
assay.   
The ELISA studies showed very low levels of TNF after 15 minutes of ischemia, 
but there was a mean increase of 9.24 pg/ml in the levels of TNF with the post treatment 
serum samples in the ischemic model over that of control with a mean TNF level of 1.76 
pg/ml.  The mean TNF levels for the post ischemia group were higher than that of the 
control group indicating that cardiac ischemia increases the serum levels of TNF.  We 
also discovered the greater the area of ischemia—visually defined by the injection of 
trypan blue dye—the higher the levels of TNF in the serum.  This phenomenon was 
responsible for the large standard deviation for the post ischemia serum samples.  
Although close to significance, this same large variability prevented our results from 











Figure 4.  Mean arterial blood pressures for animals in the TNF ELISA studies 
showing pressures remaining at a level for the prevention of organ ischemia.  
 
 indicates a statistical difference between the control and ischemic groups at the 
14 minute mark.   * indicates a statistical difference between the 14 minute MAP 
compared to its control within the ischemic group.   Mean values are ± standard 

















Figure 5.  Bar graph representing the TNF serum levels.  To increase power and 
avoid a Type II statistical error, data was pooled from the vehicle only ischemic 
studies (which mirrored that of these ischemic studies) and added to the cardiac 
ischemic data.  TNF serum levels were statistically higher in the post ischemia 
group than that of the control indicating that cardiac ischemia increases levels of 
TNF in our ischemic model.  Pre represents the serum samples that were taken 
prior to induced ischemia, and post represents the serum samples taken after 15 
minutes of the first serum samples taken.  Mean values are ± SEM, P > 0.05. 
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increase the likelihood of committing a Type II statistical error.  To avoid this we pooled 
data from our WTACE2, TNF inhibition studies (Chapter VII) using the vehicle only pre 
and post cardiac ischemia data.  The pooled vehicle only data mirrored that of these pre 
and post cardiac ischemic TNF serum levels illustrating the vehicle (0.5% methocellulose 
and 2% Tween 80) had no impact on the TNF serum levels.  Figure 5 shows the bar 
graph representing TNF serum levels of the ELISA studies including pooled data.  The 
graph shows a significant (P < 0.05) increase in levels of TNF after coronary occlusion 
with a mean increase of 15.79 pg/ml in serum TNF post treatment over that of controls 
with a mean value of 2.36 pg/ml. 
4.4 Discussion 
Although TNF levels were low and there were only small changes in pre versus 
post serum samples and control versus ischemic serum samples, these studies found there 
are increased levels of TNF over that of control in as little as 15 minutes of cardiac 
ischemia without reperfusion. We feel there would have been substantial increased TNF 
levels in the rats with induced ischemia had there been reperfusion to the ischemic site as 
found in other animal studies [8], [9], [10], which would be a model similar to that seen 
with CPB.  Our model of ischemia without reperfusion probably better represents the 
majority of heart disease caused by that of an MI [60].   Also we feel there would be 
higher levels of TNF if we would have extended the time for the ischemic model, which 
has additionally been shown in other animal studies [8], [9], [10].  Human studies as well 
have noted a correlation between the levels of TNF and the duration of cardiac ischemia 
[5].  Observations have also shown, as our studies did, that the degree of myocardial 
injury determined the levels of TNF release [4] 
 41
Because of the nature of cytokines it is not surprising that even at low levels, 
cytokines can cause a myriad of events due to their ability to initiate a variety of cascades 
that can amplify their actions.   The bioactivities exerted by cytokines such as TNF are 
extremely diverse, showing remarkable organ and cell specificity.  There is strong 
evidence that the response of a cell type to a given cytokine is greatly influenced by its 
microenvironment [17].  So in essence a little can go a long way. 
In conclusion, these studies show quantitatively that serum TNF does go up over 
control due to induced cardiac ischemia.  We found only small increases, but these 
increases were consistent.  Also found was TNF levels went up as cardiac injury 
increased.  These studies are consistent with other research showing that the cytokine, 
TNF, does in fact go up due to myocardial injury [5], [3], [27], [8], [9], [10]. 
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Chapter V 
DETECTION OF PARP TO DETERMINE APOPTOSIS IN KIDNEY 




Apoptotic cells do not display a random or chaotic degradation of all cellular 
proteins.  On the contrary, at an early stage of apoptosis, caspases cleave a select band of 
target proteins at very specific sites, often making two or more identifiable fragments.  
PARP, a nuclear DNS-binding protein that detects DNA strand breaks and functions in 
excision repairs, is among the first targeted protein shown to be purposely cleaved during 
apoptosis to form a signature 89 kD and 24 kD fragments (Figure 3) [56], [61].  Cleavage 
of PARP is one of the earliest detectable protein-degradation events and can be detected 
within 15 minutes of apoptotic activation [56].  Also it has recently been suggested that 
cleaved PARP can contribute to the machinery of apoptosis by either the 89 kD fragment 
exhausting the cell of needed energy or by the 24 kD fragment blocking DNA repair [56], 
[62], [63], [64]. 
The objective of this study was to examine if there is injury to the kidney after 
cardiac ischemia.  Because PARP has become an early marker and a research hallmark 
indicating apoptosis [20], [50], [2], [49], [56] this investigation used Western blot 
analysis to detect cleaved PARP. 
5.2 Methods 
5.2.1 Myocardial Ischemic Model 
 Two groups of six adult, male Sprague Dawley rats weighing between 500 to 650 
grams were used as a control group or a cardiac ischemic group.  Both groups were 
anesthetized with isoflourane/oxygen (2% volume/volume) at two liters per minute 
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followed by an i.p. injection of ketamine HCl (100 mg/kg of body weight) and zylazine 
HCl (10 mg/kg of body weight).  Both groups had catheters placed in the external jugular 
vein for intravenous injections of medication if necessary, and the carotid artery for 
monitoring the animals’ arterial pressures.  Both groups had a tracheotomy preformed 
should assisted breathing be required.  With the cardiac ischemic group the animals’ 
chests were opened by way of left thoracotomy and placed on mechanical ventilation.  
Once the animals’ ventilation was maintained the interventricular coronary artery was 
occluded with a silk suture.  After 15 minutes of coronary ischemia the kidneys were 
isolated, removed, rinsed in chilled normal saline, rapidly frozen in liquid nitrogen and 
stored at -80°C to be further processed for Western blot analysis.  To insure ischemia was 
accomplished, trypan blue dye was injected into the coronary artery to determine the 
ischemic area.  With the control animals, the kidneys were removed and handled the 
same as cardiac ischemic kidneys 15 minutes after the placement of carotid artery 
catheter. 
5.2.2 Western Blot Analysis 
 Kidney tissue (stored at –80°C) was pulverized into a powder using liquid 
nitrogen and placed in a 50 milliliter tube containing lysis buffer  (50mM Tris [pH 7.4], 
2% Triton-X, 1M NaCl, 5 mM EDTA, 15% glycerol, and 1mM NaF) with protease 
inhibitors (PI) added (10 µg/ml aprotinin, 20 µg/ml leupeptin, 10 µg/ml trypson type II-
O, 10 µg/ml trypsin type II-S, and 10 µg/ml pepstatin, Sigma, St. Louis, MO).  Tissue 
was then homogenized and dounced.  Tissue was allowed to incubate in the lysis buffer 
for two hours on ice to ensure all cell membranes where adequately lysed before 
centrifuging (10,000 x g) for one hour to eliminate all large particles.  Supernatant from 
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centrifuged samples were decanted and place in appropriately labeled tubes.  Protein 
levels of each sample were determined by Bradford protein assay.  Protein standard curve 
was analyzed by version 3.0 GraphPad Prism.  Proteins were resolved by 4-15% precast 
SDS polyacrylamide gel (Bio-Rad Laboratories, Chicago, IL) electrophoreses.  After 
electrophoreses, samples were transferred to PVDF membranes (Bio-Rad Laboratories, 
Hercules, CA) and membranes were allowed to dry.  Blots were then incubated with 
primary antibody PARP (Cell Signaling Technology, Beverly, MA) blocked with 5% 
skimmed milk mixed in TBST with 0.025% Tween 20 overnight.  The blots were than 
rinsed with TBST and incubated in secondary antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA) blocked with 5% skimmed milk mixed in TBST with 0.025% Tween 20 for 
one hour and rinsed with TBST.  After rinsing, the blots were developed with the 
enhanced chemiluminescence (Amersham Biosciences, England).  Exposure time to film 
(Kodak Scientific Imaging film, Fisher Scientific, Houston TX) was determined by the 
degree of signal.  Density of bands of interest from exposed film were measure by Bio-
Rad G-710 Calibrated Imaging Densitometer. 
5.3 Results 
 
MAP were continually monitored for all the animals in this study.  Figure 6 shows 
a graph of the MAP for both groups (control and ischemic).  The graph illustrates there is 
no statistical significance between the control and ischemic groups, but there was a 
statistical significance found at the 15 minute pressure compared to its control pressure 
within the control group.  Although this one measure statistically shows significance, we 
feel there is no biological significance and we were confident that animal blood pressures 
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remained in a range where there was no organ damage due to ischemia after coronary 
occlusion. 
Figure 7 shows the effect of cardiac ischemia on PARP cleavage in the kidney 
and is a Western blot that represents the data gathered in these studies.  There is an 
increase in both the PARP fragments of 89 kD and 24 kD in cardiac ischemic renal tissue 
over that of control kidney tissue.  The control lane of Figure 7A shows the intact 116 kD 
of PARP where as in the cardiac ischemic lane there are undetectable amounts of the 
complete protein.  This blot also illustrates there is a substantial increase of the 89 kD 
PARP fragment in the kidney tissue due to cardiac ischemia.  Figure 7B represents the 
increase seen in the 24 kD fragment of PARP in kidney tissue from animals that 
underwent cardiac ischemia, but undetectable in the control kidney tissue. 
Western blot analysis of cardiac ischemic kidney tissue compared to that of 
control kidney tissue shows there is an increase of apoptotic signaling in the cardiac 
ischemic kidney tissue over that of control in as little as 15 minutes.  As seen in the graph 
of Figure 8, PARP signaling shows a mean densitometer reading of 5.4 in the cardiac 
ischemic group over that of the 0.8 mean reading for the control group producing an 
approximate 6.75 fold increase in apoptotic signaling in the kidney due to cardiac 
ischemia. 
5.4 Discussion 
PARP is considered an early indicator and is an accepted marker for apoptosis 
[20], [50], [2], [49], [56].  Our lab, as did other studies [56], showed that within 15 
minutes of an insult cleavage of PARP can be seen.  Whether these increases in cleaved 












Figure 6.  Mean blood pressures for animals in the PARP studies showing 
pressures remaining at a level for the prevention of organ ischemia.  * indicates a 
statistical difference between the 15 minute MAP compared to its control within 




determined, but as indicated by this investigation there is clearly an increase in the 
initiation of apoptosis caused by cardiac ischemia without reperfusion.   
Also seen by our Western blot analysis are both the cleaved products of PARP (89 
kD and 24 kD), and if recent studies are correct in their implication of PARP fragments 
contributing to apoptosis [56], [62], [63], [64], the finding of both these PARP fragments 
would further guarantee apoptotic success in the kidney due to myocardial ischemia. 
 Eventual studies need to be done to look at PARP (as a sign of apoptosis) under 
conditions of cardiac ischemia with reperfusion.  Reperfusing the myocardium after an 
ischemic event, such as that seen in CPB, shows considerably higher levels of cytokines, 
like TNF, released systemically.  There are also increased  levels of systemic cytokines 
correlated   with   the   ischemic  time  span  of  the  myocardium [4], [5].  Subsequently  
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              Kidney Samples 
 











Figure 7.  Western blot exposed film showing the cleaved fragments of PARP. A 
The 89 kD band is one of the cleaved products of PARP and is visibly seen at 
higher levels in the cardiac ischemic kidney samples then in the control.  B The 
24 kD band is the other cleaved product of PARP as a result of apoptotic 
activation, and is seen largely increased in the kidney tissue after cardiac 
ischemia where as there are undetectable levels in the control kidney.  Clearly 
seen by this Western Blot is an increase in apoptotic signaling, determined by the 




















Figure 8.  PARP shows a mean densitometer reading of 5.4 for the cardiac 
ischemic kidney tissue over that of mean readings of 0.8 for the control kidney 
tissue producing an approximate 6.75 fold increase of apoptotic signaling in the 
kidney due to cardiac ischemia.   
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further investigations should also be done on kidney tissue creating a time course of renal 




RENAL CELLS EFFECTED BY CARDIAC ISCHEMIA 
6.1 Introduction 
 Our investigation as well as other studies have shown increases in TNF levels as a 
result of cardiac ischemia [3], [4], [5], [6], [8], [9], [10].  And it is thought that the release 
of such cytokines can cause injury to other organ systems like the kidneys [3], [7].  To 
date there has been no immunohistochemistry studies on kidney tissue harvested after 
cardiac ischemia to determine 1) if there is injury to the kidney, and 2) which cells in the 
kidney are injured.   
 In normal kidneys the TNFR-1 is detected in the endothelium of the glomeruli 
with weak staining in the distal convoluted tubules (DCT).  The distribution of TNFR-2 
differs form TNFR-1.  TNFR-2 shows no positive reaction in the glomeruli, but a weak 
reaction in the proximal convoluted tubules (PCT).   
 In the inflammatory process, it appears the TNF receptor expression in the kidney 
varies significantly from that of normal kidney[65], and there seems to a be disease 
specific expression of TNF receptors [66].  For example, in acutely rejecting renal 
allograft there was an increased staining for TNFR-2 on the descending loops of Henle, 
DCT, and collecting ducts in the medulla.   In the cortex, the TNFR-1 expression was 
diminished in glomeruli [65].  In proliferative lupus nephritis, TNFR-1 was strongly 
increased in the glomeruli compared to non-diseased kidneys [66].   As the pattern of 
TNF receptor expression changes so should the area in which TNF will influence the 
kidney.   
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 Immunohistochemistry studies have shown that different insults on the kidney 
show different forms of renal injury.  Endotoxemia induced by lipopolysaccharide (LPS) 
produced glomerular injury where as renal ischemia caused injury to tubular cells [25].   
Cisplatin, a chemotherapeutic widely used treatment for variety of malignancies and 
shown to induce renal dysfunction via TNF, was found to cause severe tubular injury 
reflected by cast formation, loss of brush border membranes, sloughing of tubular 
epithelial cells, and dilation of tubules [67]. 
 The purpose of this study was to see histologically if the kidney does show signs 
of injury and demonstrate where such injury may take place after 15 minutes of induce 
cardiac ischemia (Aim #3).  Because active caspase 3 is thought to be a key effector 
protein of the apoptotic machinery [2], we have chosen to use it for this investigation.  
Inactive forms of caspase 3 are found in all cells; therefore, in our studies the paraffin 
imbedded kidney tissue was probed with the active form of caspase 3.  PARP, one of the 
most important targets of caspase 3 [49] as well as an established hallmark of apoptosis 
[20], [50], [56], [2], [49], was used in these studies to indicate which renal cells were 
undergoing injury, as signified by apoptotic signaling. 
6.2 Methods 
6.2.1 Myocardial Ischemic Model 
 Two groups of three adult, male Sprague Dawley rats weighing between 400 to 
600 grams were used as a control group or a cardiac ischemic group.  Both groups were 
anesthetized with isoflourane/oxygen (2% volume/volume), i.p. injected with ketamine 
HCl and zylazine HCl.  Both groups were prepped as those in the prior study with 
placement of catheters in the external jugular vein and the carotid artery, and tracheotomy 
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preformed.  As with the prior study, one group was subject to cardiac ischemic and the 
other group did not and was considered control animals. After 15 minutes the kidneys 
were harvested from both groups, rinsed in chilled normal saline, and place in buffered 
fixative for immunohistochemistry.   
6.2.2 Immunohistochemistry
All kidney tissue was fixed in buffered formalin for 12 to 18 hours, dehydrated in 
ascending series of ethanol concentrations (75%, 95%, 100%) and xylene, and then 
embedded in paraffin wax.  Seven-micrometer sections were dewaxed in xylene and 
rehydrated through a descending series of ethanol concentrations (100%, 95%, 75%).  
Sections were then washed in deionized water before the labeling procedure.  
Endogenous peroxidase was blocked by placing sections in 0.3% peroxide diluted with 
methanol for 30 minutes and rinsed with PBS.  Nonspecific antibody binding was 
blocked by incubating sections for one hour in 2% normal blocking serum diluted in PBS 
(1:50 dilution).  Sections were then incubated in primary antibody (active caspase 3 or 
cleaved PARP, Promega, Madison, WI) diluted in PBS (1:100) for 30 minutes to one 
hour at room temperature.  After sections were rinsed of primary antibody with PBS, 
secondary antibody was applied to sections diluted in PBS and blocking serum incubating 
for 30 minutes.  The sections were then stained using ABC-peroxidase substrate kit 
(Vectastain elite, Vector Laboratories, Burlingame, CA) and rinsed.  3,3′-
diaminobenzidine tetrahydrochloride (DAB, Vector Laboratories, Burlingame, CA) was 
applied to the sections and allowed to incubate for 15 minutes or until desired stain 
intensity developed.  The sections were rinsed with PBS, dehydrated in graded alcohols 
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(75%, 95%, 100%), counterstained with hematoxylin (for visualization), and 
coverslipped. 
6.3 Results 
 MAP were continually monitored for all the animals in this study.  Figure 9 shows 
a graph of the MAP for the two groups (control and ischemic).  The graph illustrates 
there is no statistical significance between the control and ischemic groups, but there was 
statistical significance found at the 15 minute blood pressure compared to its control 
blood pressure within the control group.  Although this one measure statistically shows 
significance, we feel there is no biological significance and we were confident that 
animal blood pressures remained in a range where organs were properly perfused.  
 Kidneys from the ischemic heart group demonstrated increases in both Caspase 3 
(Figure 10) and PARP (Figure 12) activity compared to kidneys from control rats 
(Figures 11 and 13).   Active caspase 3 and cleaved PARP were localized to the cortex of 
the kidney with most all activity found in the proximal tubules.    
 The activation of caspase 3 can be executed by caspase 8 or caspase 9 complex 
resulting in the fragmented 17 kD active form of caspase 3 and was the form used in 
these studies.  Figure 10 is a slide representative of kidney tissue from the cardiac 
ischemic group.  Increases in activated caspase 3 is found to be localized in the cortex of 




















Figure 9.  Mean blood pressures for animals in the ischemic studies showing 
pressures remaining at a level for the prevention of organ ischemia.  * indicates a 
statistical difference between the 15 minute MAP compared to its control within 
the control group.  Mean values are ± SEM. 
Mean Arterial Blood Pressures in
Immunohistochemistry  Studies



















other hand, Figure 11 shows kidney tissue from the control group to be mainly clear of 
any active caspase 3 signaling.  Also seen in Figure 10 are the beginnings of renal injury 
illustrated by the scalloping brush border of proximal tubule epithelial cells (green 
arrow).  This renal injury is not seen in Figure 11 of the control kidney tissue. 
 Because of our findings with Western blot analysis of increased levels of cleaved 
PARP in kidney tissue following cardiac ischemia (Chapter V), we were confident that 
we would see PARP signaling in the kidney tissue of the cardiac ischemic group, and we 
do.  As with Caspase 3 the cleaved PARP staining was found largely in the proximal 
tubules of the renal cortex in kidney tissue from animals that underwent cardiac 
ischemia (Figure 12).  In contrast, the renal tissue collected from animals of the control 
group   showed  a   definite   reduction  in   the  amount  of  PARP  staining   (Figure 13).     
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                                         Caspase 3 Found in Cardiac Ischemic Group 
 
 
Figure 10.  Active caspase 3 
after 15 minutes of cardiac  
ischemia.  The red arrows  
are pointing to the caspase 
3 signaling localized to the  
cortex of the kidney with 
most activity found pre- 
dominately in the proximal  
tubules.  The green arrow 
is pointing to brush border 
scalloping of proximal 
tubule epithelial cells  
indicating the beginnings  










Figure 11.   Control tissue 
stained for active caspase 3. 
This slide is representative 
of the overall kidney tissue 
for the control group.  The 
brown freckling represent- 
ing activated caspase 3 as 
seen in the cardiac  
ischemic kidney tissue  
(Figure 10) is absent in the  
control tissue slides.  Plus  
the renal epithelial cells  
continue to look healthy;  
no brush border scalloping 
observed in the cardiac  
ischemic kidney tissue 












Figure 12.  Cleaved PARP 
after 15 minutes of cardiac 
ischemia.  The red arrows  
pointing to some of the  
PARP staining.  The stain- 
ing was mainly seen in the  
proximal tubules in much  
the same pattern as that of 

















Figure 13.  Control tissue 
stained for cleaved 89 kD 
fragment of PARP.  This 
slide is characteristic 
of the overall kidney tissue 
for the control group.  The 
brown freckling represent- 
ing cleaved PARP as 
seen in the cardiac ischemic 
kidney tissue (Figure 12) is  
not present in the control  








Caspase activation results in cleavage of PARP into two characteristic fragments of 
molecular mass 85-89 kD and 24-26 kD [20], [50], [56], [2], [49], in our study the 
paraffin imbedded kidney tissue was probed with the cleaved 89 kD form. 
6.4 Discussion 
 
 For the first time, these immunohistochemical studies show the renal cells most 
effected by an injured heart and implicates the kidney being at risk for injury after acute 
coronary ischemia.  Because of the unique ability of the myocardium to release cytokines 
when injured indicate that these cells can and, as shown by these studies, do increase 
apoptotic signaling in renal cells.  These lethal signals could cause renal cell death or 
dysfunction.   
 The injury to the kidney caused by cardiac ischemia appears to focus in the 
proximal tubules of the renal cortex.  The apoptotic signally discovered in our studies 
were not global but found in small patches of proximal tubules throughout the cortical 
portion of the kidney.  The extent of the injury we see after only 15 minutes of cardiac 
ischemia would probably not have much of an effect on a healthy kidney, but for diseased 
or aged kidneys having already lost some of their function this could be critical. 
 In a preliminary study done in our lab, we prepped kidney tissue for 
immunohistochemistry harvested after one-hour post TNF infusion study.  We then 
probed the tissue with the same active caspase 3 and cleaved PARP as in our cardiac 
ischemic studies.  What we found was renal injury much like that described in the 













Figure 14.  Immunohistochemistry 
slides showing renal tubular injury 
post one hour TNF infusion.  
The injury was localized to the renal 
cortex.  A. The red arrows point to 
proximal tubules that are shedding  
their brush borders.  B. The blue  
arrows point to cast formation and  
















Further immunohistochemical studies need to be done extending the duration of 
cardiac ischemia to see if it reflects the same type of renal injury our lab found with the 
one-hour TNF infusion histological studies.   Since studies have already shown a 
correlation between the length of time for myocardial ischemia and the levels of harmful 
cytokine release [4], [5], additional studies need to be done to measure if the degree of 




APOPTOTIC SIGNALING IN THE KIDNEY AFTER 




Cardiorenal syndrome is a term used by clinical researchers who observed that a 
small percentage of patients suffered from renal dysfunction or renal failure following 
CPB [6], [3],  [4].  This same syndrome has been seen in patients suffering from heart 
failure [7].  It is also the thought of these researches that TNF plays a major role in renal 
injury.   
 The heart has been found to be a major source of TNF.  Cardiac myocytes 
themselves produce TNF, which is nearly evenly distributed between cardiomyocyte and 
resident cardiac macrophage cell types.  Under ischemic stress, the heart can release this 
TNF causing potential dysfunction to other organs such as the kidneys.  Once in the 
kidney, TNF can be highly destructive by increasing glomerular albumin permeability, 
causing glomerular fibrin deposition, stimulating cellular filtration, inducing the synthesis 
of other proinflammatory mediators, and reducing glomerular blood and glomerular 
filtration rate [3], [68].  
 To this point, our studies have shown there is a consistent increase in serum TNF 
levels after cardiac ischemia (Chapter IV:  Quantitate TNF Levels), we have seen an 
approximate 6.75 fold increase over control in levels of PARP in the kidney due to 
cardiac ischemia (Chapter V:  Detection of PARP to Determine Apoptosis in Kidney 
tissue After Coronary Ischemia), and we have determined histochemically the renal cells 
most effected by cardiac ischemia (Chapter VI:  Renal Cells Effected by Cardiac 
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Ischemia).  The purpose of this study is to look at the consequence of cardiac ischemia on 
renal tissue as well as investigate the role TNF plays in the process.  Renal injury due to 
cardiac ischemia will be determined via Western blot analysis by looking at apoptotic 
signaling indicated by increased levels of active caspases 2, 3, and 9 (Aim #4.a.).   To 
investigate the significance of TNF in apoptotic signaling found in the kidney following a 
cardiac ischemic event we will first inhibit the release of TNF from the injured 
myocardium via WTACE2, a metalloproteinase inhibitor specific for TACE.  Inhibition 
of TNF is determined by serum levels of TNF tested by an ultrasensitive TNF ELISA kit 
comparing serum from animals undergoing cardiac ischemia that were injected by 
WTACE2 to those animals undergoing cardiac ischemia who were injected with the 
vehicle only.  Kidney tissue was harvested from these same animals and prepped for 
Western blot analyses to measure apoptotic signaling, determined by caspases 2, 3, and 9, 
as well as cleaved PARP (Aim #4.b.).  Comparisons in apoptotic signaling levels are 
done between the TNF inhibited tissue with tissue that TNF is not inhibited.  If TNF has a 
significant role in cardiorenal syndrome we should see a substantial reduction in 
apoptotic signaling when TNF is inhibited. 
To take the investigation of TNF and its importance in renal injury after cardiac 
ischemia a step further, we eliminated the cardiac ischemic event.  In two groups of six 
animals we either infused TNF or normal saline.   The kidney tissue from both groups 
was harvested and prepped for Western blot analysis to once again determine apoptotic 
signaling by measuring active forms of caspases 2, 3, and 9, and cleaved PARP (Aim 
#4.c).  Once more, if TNF is important in the harming of the kidney after acute coronary 
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ischemia, the TNF infused tissue should show apoptotic signaling patterns similar to that 
seen in kidney tissue after cardiac ischemia. 
7.2 Methods 
7.2.1 Myocardial Ischemic Model 
 Two groups of six adult, male Sprague Dawley rats weighing between 500 to 650 
grams were used as a control group or a cardiac ischemic group.  Both groups were 
anesthetized with isoflourane/oxygen (2% volume/volume) at two liters per minute 
followed by an i.p. injection of ketamine HCl (100 mg/kg of body weight) and zylazine 
HCl (10 mg/kg of body weight).  Both groups had catheters placed in the external jugular 
vein for intravenous injections of medication if necessary, and the carotid artery for blood 
draws and monitoring the animals’ arterial pressures.  Both groups had a tracheotomy 
performed should assisted breathing be required.  With the cardiac ischemic group the 
animals’ chests were opened by way of left thoracotomy and placed on mechanical 
ventilation.  Once the animals’ ventilation was maintained the interventricular coronary 
artery was occluded with a silk suture.  After 15 minutes of coronary ischemia the 
kidneys were isolated, removed, rinsed in chilled normal saline, rapidly frozen in liquid 
nitrogen and stored at -80°C to be further processed for Western blot analysis.  To insure 
ischemia was accomplished, trypan blue dye was injected into the coronary artery to 
determine the ischemic area.  With the control animals, the kidneys were removed and 





7.2.2 Infused TNF-α Model
One of the methods we used to investigate the significance of TNF in the role of 
kidney injury due to myocardial ischemia was to infuse TNF without induced ischemia 
and compare the apoptotic signaling to that of the cardiac ischemic kidney tissue.   Two 
groups of six adult mail Sprague-Dawley rats (500-650g body weight) were anesthetized 
first with isofluorane/oxygen (2% volume/volume) at 2-liters per minute gases at 1 
atmosphere followed by an i.p. injection of ketamine HCl (100 mg/kg body weight) and 
xylazine HCl (10 mg/kg body weight).  Catheters were placed in the external jugular vein 
for intravenous injections of medications if necessary, and the carotid artery for 
monitoring the animals mean arterial pressures.  A tracheotomy was performed without 
the animal being placed on mechanical ventilation because animal did not need 
ventilation assistance since the chest was not opened to perform coronary ligation.   2ng 
of TNF per 1ml of extracellular fluid was diluted in 2 mls of normal saline and 
intravenously injected via the external jugular catheter for a period of 15 minutes.  
Immediately after the TNF infusion the kidneys were harvested, rinsed in chilled normal 
saline, rapidly frozen in liquid nitrogen, and stored at -80°C for Western blot analysis.  
We followed the same procedures for the control animals except we infused normal 
saline only. 
7.2.3 Western Blot Analysis 
 Kidney tissue (stored at –80°C) was pulverized into a powder using liquid 
nitrogen and placed in a 50 milliliter tube containing lysis buffer  (50mM Tris [pH 7.4], 
2% Triton-X, 1M NaCl, 5 mM EDTA, 15% glycerol, and 1mM NaF) with protease 
inhibitors (PI) added (10 µg/ml aprotinin, 20 µg/ml leupeptin, 10 µg/ml trypson type II-
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O, 10 µg/ml trypsin type II-S, and 10 µg/ml pepstatin, Sigma, St. Louis, MO).  Tissue 
was then homogenized and dounced.  Tissue was allowed to incubate in the lysis buffer 
for two hours on ice to ensure all cell membranes where adequately lysed before 
centrifuging (10,000 x g) for one hour to eliminate all large particles.  Supernatant from 
centrifuged samples were decanted and place in appropriately labeled tubes.  Protein 
levels of each sample were determined by Bradford protein assay.  Protein standard curve 
was analyzed by version 3.O GraphPad Prism.  Proteins were resolved by 4-15% precast 
SDS polyacrylamide gel (Bio-Rad Laboratories, Chicago, IL) electrophoreses.  After 
electrophoreses, samples were transferred to PVDF membranes (Bio-Rad Laboratories, 
Hercules, CA) and membranes were allowed to dry.  Blots were then incubated with 
primary antibody (caspase 2, caspase 3, caspase 9—Santa Cruz Biotechnology, Santa 
Cruz, CA, and cleaved PARP—Cell Signaling Technology, Beverly, MA) blocked with 
5% skimmed milk mixed in TBST with .025% Tween 20, for 3 hours to overnight.  The 
blots were than rinsed with TBST and incubated in secondary antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) blocked with 5% skimmed milk mixed in TBST with 
.025% Tween 20 for one hour and rinsed with TBST.  After rinsing the blots were 
developed with the enhanced chemiluminescence (Amersham Biosciences, England).  
Exposure time to film (Kodak Scientific Imaging film, Fisher Scientific, Houston TX) 
was determined by the degree of signal.  Density of bands of interest from exposed film 
were measure by Bio-Rad G-710 Calibrated Imaging Densitometer. 
7.2.4 TNF Inhibition
 Once again to substantiate the role of TNF in Cardiorenal syndrome we inhibited 
TNF release by way of WTACE2, a novel metalloproteinase inhibitor specific for TACE, 
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developed and donated by Wyeth-Ayerst Research (Pearl River, NJ).  Two groups of five 
male Sprague-Dawley rats (200-400 g body weight) were either injected i.p. with a dose 
of 100 mg/kg of WTACE2 in a vehicle containing 0.5% methocellulose and 2% Tween 
80 (Fisher Scientific, Houston, TX) or with the vehicle containing 0.5% methocellulose 
and 2% Tween 80 only 30 minutes prior to induced cardiac ischemia.  After 30 minutes 
post designated i.p. injection, the animal was made subject to induced ischemia as 
described above.  Also to see what affect the WTACE2 would have on kidney tissue 
without induced cardiac ischemia we did three control animals where we gave i.p. 
injection of WTACE2 with described vehicle 30 minutes prior to prepping for a sham 
control (without the coronary occlusion).  After 15 minutes with or without cardiac 
ischemia, kidneys were harvested, rinsed in chilled normal saline, immediately frozen in 
liquid nitrogen, and stored at -80°C for future preparation for Western blot analysis.   
7.2.5 Ultrasensitive TNF ELISA
 To ensure the WTACE2 did in fact lower the serum levels of TNF, from all the 
above-mentioned animals (cardiac ischemia with WTACE2, cardiac ischemia without 
WTACE2, and control with WTACE2) there was a blood draw prior to treatment and 15 
minutes post treatment.  Pre and post treatment blood samples were allowed to clot for 30 
minutes, after 30 minutes each sample was centrifuged 1000 x g for 10 minutes.  Serum 
was then removed and place in clean, appropriately labeled tubes.  Serum samples were 
stored at -4°C or immediately tested for TNF levels with the Ultrasensitive TNF ELISA 
kit.  100 µL of each prepared serum sample was place in its designated well of a 96 well 
plate from the Ultrasensitive TNF ELISA Kit (Bio Source International, Camarillo, CA) 
along with the TNF standards provided by the kit and prepared according to the kit’s 
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protocol.  After completing the ELISA protocol, the wells used in the 96 well plate were 
read by Dynatech MR 700 microplate reader.   Statistical analysis using Two-way 
ANOVA with repeated measures is used to determine significance. 
7.3 Results 
 Western blot analysis of cardiac ischemic kidney tissue compared to that of 
control kidney tissue shows there is an increase of apoptotic signaling in the cardiac 
ischemic kidney tissue over that of control in as little as 15 minutes.  By constant 
monitoring of the animals’ blood pressures throughout the entire procedure, we were 
confident animal blood pressures fell within parameters of safe MAP to properly 
maintain perfusion to the kidney.   Figure 15 shows a graph of the MAP for the two 
groups (control and ischemic).  The graph demonstrates there is no significant difference 
between the control group and the ischemic group, but there was a statistical difference in 
the 15-minute pressure compared to its control pressure within the control group.  While 
there shows to be a statistical difference in this area, we feel there is no biological 
significance.  
Figure 16 shows an example of a Western blot exposed film probed with the 
primary antibody actin to illustrate even protein loading.  This procedure is universally 
utilized in protein studies to maintain accuracy in the amounts of protein used for each 
sample when measuring protein levels with Western blot analysis.  We used this process 
for each blot in all of our protein studies.  The actin primary antibody used for our studies 
fell within the 43-45 kD range.  Once we probed each blot with actin, the blots were then 
developed with enhanced chemiluminescence and exposed to film. The density of the 
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Figure 15.  Mean arterial blood pressures for animals in the cardiac ischemic 
studies showing pressures remaining at a level for the prevention of organ 
ischemia.  .  * indicates a statistical difference between the 15 minute MAP 
compared to its control within the control group.  Mean values are ± SEM. 
Mean Arterial Blood Pressures in
Ischemic Studies
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Figure 16.  Actin.  Western blot exposed film showing even loading determine by 
probing blot with the primary antibody of actin.  This procedure was done for 
each blot to ensure even loading for the cardiac ischemic studies. 
 
As shown in Figure 1, caspase 3 cleavage and subsequent activation is 
targeted by caspase 8, caspase 2, and caspase 9 complex suggesting that caspase 3 
plays  a  dominate  role  in  apoptosis  [47],   [2],  [22],  [48],  [20].    Western blot  
 66
   Kidney Samples 









Figure 17.  Caspase 2.  Western blot exposed film showing the 24-26 kD band 
for Caspase 2 with cardiac ischemic kidney tissue signal being higher than that of 
control kidney tissue. 
 
 
analysis of caspase 3 (Figure 19) in our investigation shows there is an increase in 
caspase 3 in cardiac ischemic kidney tissue over the control kidney tissue.  This is a 
similar pattern to what we see with levels of caspase 2.   Figure 17 shows an example of 
Western blots of caspase 2.  The activated caspase 2 fragment falls in the range of 24-26 
kD, and as seen in Figure 17, activated caspase 2 levels are higher in cardiac ischemic 
renal tissue than that of control.  These blots illustrate there is an increase in caspase 2 
signaling with a mean densitometer reading of 8.6 in the cardiac ischemic tissues over 
that of the 1.2 mean reading of control tissues, producing an approximate 7 fold increase 
(Figure 18).    
The caspase 3 primary antibody used for these studies was the activated 17 kD 
caspase 3.  Figure 19 shows an example of the Western blot analysis for caspase 3 where 
there is a distinct increase in the levels of active caspase 3 in the renal tissues from the 
cardiac ischemic group over that of the control group.  The mean densitometer reading 
for cardiac ischemic kidney tissue was 4.6 compared to the mean reading for control 
kidney tissue of 1.4.  This gives an approximate 3.3 fold increase in caspase 3 signaling 



















Figure 18.  Caspase 2 shows a mean densitometer reading of 8.6 for the cardiac 
ischemic kidney tissue over that of mean readings of 1.2 for control kidney tissue 
producing an approximate 7 fold increase of Caspase 2 signaling in the kidney 
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Figure 19.  Caspase 3.  Western blot exposed film showing the 17 kD band 
indicative of activated Caspase 3.   The cardiac ischemic kidney samples clearly 
have a strong caspase 3 signal compared to that of the control kidney samples. 
 
 In order to examine if there is any mitochondrial amplification in the apoptotic 
signaling found in kidneys for our cardiac ischemic research model, we looked at caspase 
9.  For caspase 9 to be activated it must be combined with the released mitochondrial 
cytochrome c along with the cofactor Apaf-1 (Figure 1).   Once caspase 9 has complexed 
with cytochrome c and Apaf-1 (also known as an aposome) it can then activate caspase 3.   






















Figure 20.  Caspase 3 shows a mean densitometer reading of 4.6 for the cardiac 
ischemic kidney tissue compared with the mean reading of 1.4 for the control 
kidney tissue giving an approximate 3.3 fold increase in caspase 3 signaling in 
the cardiac ischemic samples over that of the control samples.   
 
bands at 10, 35, and 37 kD.   Studies show the 35 kD fragment is associated with the 
complex of cytochrome c and Apaf-1 and the 37 and 10 kD fragments are generated by 
activated caspase 3 [69], [50]. 
Our studies did in fact find there is increased mitochondrial apoptotic 
amplification in the cardiac ischemic renal tissue over that of control as signified by the 
increase in activated caspase 9.  Figure 21 shows an example of Western blots in our 
investigation demonstrating the marked increase in active caspase 9 (37 and 35 kD) 
signaling in the cardiac ischemic renal tissue over that of control.  When these blots were 
read on a densitometer, the mean reading for caspase 9 for the cardiac ischemic kidney 
tissue is 8.4 compared to the densitometer reading of 2.6 for the control kidney tissue.  
This gives an approximate 3.2 fold increase in active caspase 9 for the cardiac ischemic 
tissue over that of the control tissue illustrated in the graph shown in Figure 22. 
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Figure 21.  Caspase 9.  Western blot exposed film showing the 35 and 37 kD 
band both active forms of caspase 9.  The 35 kD active form of caspase 9 is 
processed by the release of cytochrome c from the mitochondria and complexing 
with Apaf-1, and the 37 kD active form is mediated by caspase 3.   Both the 35 
and 37 kD bands of the cardiac ischemic kidney tissue show increased signaling 

















Figure 22.  Caspase 9 shows a mean densitometer reading of 8.4 for the cardiac 
ischemic kidney tissue over that of the mean reading of 2.6 for the control kidney 
tissue producing an approximate 3.2 fold increase of caspase 9 signaling in the 
kidney due to cardiac ischemia.  
 
In order to investigate the significance of TNF in apoptotic signaling found in the 
kidney following a cardiac ischemic event, we used WTACE2, a metalloproteinase 
inhibitor specific for TACE (the converting enzyme for TNF). To insure that the release 
of TNF was in fact inhibited by WTACE2, serum samples pre and post cardiac ischemia 
were taken and measured for levels of TNF in the same fashion as the TNF quantitative 















Figure 23.  Mean blood pressures for animals in the WTACE2 studies showing 
pressures remained at a level to prevent organ ischemia.  These animals were 
used for TNF inhibition ELISA studies and the TNF inhibition Western blot 
analysis.  Mean values are ± SEM. 
 
 
tissue for Western blot analysis to look for apoptotic signaling.  During each assigned 
treatments there was constant monitoring of the animals’ blood pressures throughout the 
entire procedure.  Figure 23 shows a graph representing the MAP for animals in the 
WTACE2 studies.  There is no statistical significant difference of MAP between the 
vehicle only or the WTACE2 groups, nor was there a significant difference within the 
groups.  We were confident that animal blood pressures remained in a range preventing 
any organ damage due to ischemia. 
The bar graph seen in Figure 24 represents the TNF levels found in serum 
collected from two groups of five rats; one group receiving i.p injection of WTACE2 and 
the other group receiving vehicle only.  Both groups were made subject to cardiac 
ischemia.  It is clear in Figure 24 the levels of TNF with the WTACE2 group remained 












Figure 24.  Bar graph representing the TNF levels found in serum collected from 
two groups of five rats, with one group receiving the TNF release inhibitor and 
the other group receiving the vehicle only.  Both groups where made subject to 
cardiac ischemia.  It is clear with these results that levels of TNF with the 
WTACE2 group remained low after cardiac ischemia, similar to the pretreatment 
serum samples.  Where as levels of TNF clearly went up after cardiac ischemia in 
the group not receiving WTACE2. These TNF ELISA studies show that 
WTACE2 was successful in preventing the release of TNF after cardiac 
ischemia. Pre represents the serum samples that were taken prior to induced 
coronary ischemia, and post represents the serum samples that were taken 15 
minutes after the tie off of the coronary occlusion.  Mean values are ± SEM. 
 
serum samples.  On the other hand, the animals receiving the vehicle only had an increase 
in post cardiac ischemic TNF serum levels over the pre treatment levels.   We feel 
confident that this study demonstrates WTACE2 inhibited the release of TNF.  
These ELISA studies, like the studies in Chapter IV, showed very low levels of 
TNF in the serum samples, but we did find increases that were consistent in serum 
samples collected after cardiac ischemia with the group who received vehicle only.  Also 
seen in these studies, which mirrored the ELISA studies in Chapter IV, was the greater 
















Figure 25.  Graph showing the pre treatment serum samples of the WTACE2 
studies resemble the TNF levels of the control serum sample from the TNF 
quantitative studies of Chapter IV.  You can also see where the post TNF levels 
in the WTACE2 post cardiac ischemic samples show TNF levels to be like the 
control sample. The pooled data of vehicle only and ischemic (Chapter IV) 
studies show that the WTACE2 TNF serum levels are significantly lower than 
that of serum levels from cardiac ischemia without inhibition. These comparisons 
illustrate that indeed WTACE2 decreased the release of TNF due to cardiac 
ischemia.  Mean values are ± SEM, P > 0.05.  
 
 
levels of TNF in the serum.  This was responsible for the large standard deviation seen in 
the post ischemia serum samples with the vehicle only group as was seen with the 
ischemic group in the TNF ELISA studies in Chapter IV.  Again close to significance, 
this same large variability prevented our results from being significant along with 
reducing the power of our study.  As explained in Chapter IV, a lowered power can 
increase the likelihood of committing a Type II statistical error.  To once again to avoid 
this we pooled the data from our ischemic studies (Chapter IV) using the cardiac 
ischemic data that mirrored the vehicle only data.  The graph of Figure 25 represents the 
control data of Chapter IV, WTACE2 data, and the pooled data of ischemic and vehicle 
only studies.  This graph demonstrates that the levels of TNF in those animals receiving 
treatment  with  WTACE2  are  significantly (P > 0.05) lower  than  the  ischemic/vehicle  
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Mean Densitometer Readings  
Samples Caspase 2 Caspase 3 Caspase 9 PARP 
w/WTACE 2.4 4.3 3.9 1.5 
w/Vehicle 3.3 7.5 5.1 2.8 
Ischemia 8.6 4.6 8.4 5.4 
Control 1.2 1.4 2.6 .8 
Con/WTACE 1.7 2.2 2.5 .8 
 
Table 1.  Mean densitometer readings of Western blot analysis of cardiac 
ischemic kidney tissue with WTACE2 (w/WTACE), cardiac ischemic kidney 
tissue with vehicle only (w/Vehicle), and the regular cardiac ischemic kidney 
tissue (ischemia).  The table illustrates there is a decrease in apoptotic signaling 
due to TNF inhibition (w/WTACE), but not as low as either the control kidney 
tissue for the ischemic studies (Control) or the control with WTACE2 
(Con/WTACE).  This table also points out that the two control tissue mean 
densitometer readings are very similar, with PARP being the same indicating 
WTACE has no effect on renal tissue alone 
 
TNF serum levels.  Also WTACE2 TNF serum levels are very similar to that seen with 
TNF levels found in the control animals shown in the TNF quantitative studies in Chapter 
IV. 
Convinced that indeed TNF was inhibited, Western blot analysis studies were 
done on the kidney tissue harvested from the same animals in the TNF inhibition ELISA 
studies.  To ensure the WTACE2 had no effect on kidney tissue, assays were done on a 
group of three rats that were i.p. injected with WTACE2.  After 15 minutes post 
placement of carotid artery catheter, without inducing cardiac ischemia, the kidneys were 
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Figure 26.  Western blot exposed film showing even loading determined by 
probing blot with the primary antibody of actin.  This procedure was done for 
each blot to ensure even loading for the WTACE2 studies.  IV—cardiac ischemic 
kidney tissue with i.p. injected vehicle only; IW—cardiac ischemic kidney tissue 
with i.p. injected with WTACE2.; Control—kidney tissue i.p. injected with 
WTACE2 without induced cardiac ischemia. 
 
Interestingly what we found was that although the release of TNF was inhibited 
there was however, an increase in the levels of apoptotic signaling, but according to 
densitometer readings of these Western blots seen in Table 1 the signaling, did not reach 
those levels seen with the cardiac ischemic animals receiving vehicle only or the animals 
from the cardiac ischemic studies.   Also notable, are the comparisons of the densitometer 
readings for control kidney tissues from the ischemic studies (of this chapter) and the 
control kidney tissues with WTACE2.  The mean densitometer readings were very 
similar, with PARP readings being the same.  We feel these readings indicate that 
WTACE2 had no direct effect on the kidney tissue.   
Figure 26 shows an example of a Western blot exposed film probed with the 
primary antibody actin to illustrate even protein loading.  This procedure was done on 
each blot for the WTACE2 studies.  The actin primary antibody used for our studies fell 
within the 43-45 kD range.  Once we probed each blot with actin, the blots were then 
developed with enhanced chemi-luminescence and exposed to film.  The densities of the 
bands of interest from exposed film were measured on a densitometer to calculate equal 





















Figure 27. Bar graph representing the mean densitometer readings of Western 
blots for caspase 2.  Kidney samples from animals that underwent induced 
cardiac ischemia after i.p. injections of WTACE2 (Isc WTACE) had a mean 
densitometer reading of 2.4, an approximate 2 fold increase of caspase 2 levels 
over control.  Kidney samples from animals that underwent induced cardiac 
ischemia after i.p. injections of vehicle only (Isc Vehicle) had a mean 
densitometer reading of 3.3, an approximate 2.7 fold increase in caspase 2 levels 
over control.  This indicates there is still apoptotic signaling even though TNF 
release has been inhibited, but not to the degree seen when TNF release is not 
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35 kD  
 
 
Figure 28.  Caspase 2. Western blot exposed film showing the 35 kD band for 
active caspase 2.  This blot illustrates there is still apoptotic signaling in the 
kidney after only 15 minutes of cardiac ischemia although the release of TNF has 
been inhibited.  This blot is also a good example of how apoptotic signaling 
increased due to a greater area of cardiac ischemia—visually defined by the 
injection of trypan blue dye.  IW#1 and IV#1 had a large area of cardiac ischemia 
where IV#2 had a much smaller area and the caspase 2 levels look much like the 
controls.  IW—cardiac ischemic kidney tissue with WTACE2; CW—kidney 
tissue i.p. injected with WTACE2 without induced cardiac ischemia; IV—cardiac 




Caspase 2 Western blot analysis (Figure 27) showed a mean densitometer reading 
of 2.4 for cardiac ischemic tissue with WTACE2 producing an approximate 2-fold 
increase over that of control from the ischemic studies with a mean densitometer reading 
of 1.2.  We continued to use the densitometer readings from the controls of the ischemic 
studies to create a standard by which to measure the densitometer readings for all the 
WTACE2 Western blot assays.  There was a mean densitometer reading of 3.3 for 
caspase 2 with the cardiac ischemic kidney tissue i.p. injected with just vehicle only 
producing an approximate 2.8 fold increase over control kidney tissue.  Western blot 
analysis of caspase 2 shows that although the release of TNF was inhibited, there is still 
apoptotic signaling over that of control.  But as can be seen by comparing the WTACE2 
kidney tissue with the vehicle only kidney tissue, there is not as great a caspase 2 signal 
when the release of TNF is inhibited.  Figure 28 shows an example of the Western blots 
done on caspase 2 for this study.  Seen with this example, there is still apoptotic signaling 
in the kidney although the release of TNF has been inhibited.  The blot in Figure 28 
demonstrates how apoptotic signaling increases due to a greater area of cardiac 
ischemia—visually defined by the injection of trypan blue dye.  Tissue from kidney 
samples IW#1 and IV#1 had a large area of cardiac ischemia where IV#2 had a much 
smaller area, and therefore, the caspase 2 levels look much like the controls.   Similar 
occurrences happened with the other apoptotic signaling indicators of caspase 3, caspase 
9, and cleaved PARP. 
Figure 29 gives an example of Western blots using the primary antibody active 
caspase 3 showing a band at the level of 17 kD.  This blot, like that of the blots of caspase 
2, illustrates there is still apoptotic signaling in the kidney after cardiac ischemia although  
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Figure 29.  Caspase 3.  Western blot exposed film showing the 17 kD band for 
active caspase 3.  This blot illustrates there is still apoptotic signaling in the 
kidney after only 15 minutes of cardiac ischemia although the release of TNF has 
been inhibited.    IW—cardiac ischemic kidney tissue with WTACE2; CW—
kidney tissue i.p. injected with WTACE2 without induced cardiac ischemia; 
























Figure 30.  Caspase 3.  Bar graph representing the mean densitometer readings of 
Western blots for caspase 3.  Kidney samples from animals that underwent 
induced cardiac ischemia after i.p. injections of WTACE2 (Isc WTACE) had a 
mean densitometer reading of 4.3, an approximate 3 fold increase of caspase 3 
levels over control.  Kidney samples from animals that underwent induced 
cardiac ischemia after i.p. injections of vehicle only (Isc Vehicle) had a mean 
densitometer reading of 7.5, an approximate 5.4 fold increase in caspase 3 levels 
over control.  As with caspase 2, results of Western blot analysis of caspase 3 
indicates there is still apoptotic signaling even though TNF release has been 




the release of TNF has been inhibited with WTACE2.  And as seen in Figure 30 the bar 
graph of densitometer readings of Western blots probed with active caspase 3, while there 
is an increase in active caspase 3 levels in the TNF inhibited group over control, it does 
not equal that of the vehicle only group.  The mean densitometer reading for WTACE2 
injected group is 4.3; an approximate 3 fold increase of caspase levels over the mean 
control densitometer reading of 1.2.  The levels of TNF were higher in the vehicle only 
group showing a mean densitometer reading of 7.5, and approximate 5.4 fold increase in 
caspase 3 levels over control.  
The Western blot of caspase 9 shown in Figure 31 is an example of the Western blots ran 
and probed with activated caspase 9 for these studies.  Much like that seen with both 
caspase 2 and 3, regardless of TNF inhibition with WTACE2, there is still active caspase 
9 as indicated by the signaling seen at 37 and 35 kD.  The bar graph in Figure 32 shows 
the densitometer readings of these same Western blots.  The kidney samples from 
animals that underwent induced cardiac ischemia after WTACE2 injections had a mean 
densitometer reading of 3.9, an approximate 1.5 fold increase of the control densitometer 
reading of 2.6.  Kidney samples from animals that underwent induced cardiac ischemia 
after injections of vehicle only had a mean densitometer reading of 5.1, and approximate 
2 fold increase in caspase 9 levels over control.    
An example of Western blots probed with cleaved PARP (an early marker for 
apoptosis) is seen in Figure 33.  As mentioned in Chapter V and shown in Figure 3 of 
Chapter II, PARP is cleaved during apoptosis to form 89 kD and 24 kD fragments.   The 
PARP Western blot example in Figure 33 shows the 24 kD band.  This blot, as well as the 
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Figure 31.  Caspase 9.  Western blot exposed film showing the 37 and 35 kD 
bands for active caspase 9.  This blot as well illustrates there is apoptotic 
signaling in the kidney after only 15 minutes of cardiac ischemia regardless of 
the inhibition in the release of TNF.   Also the presence of caspase 9 indicates the 
apoptotic amplification via the mitochondria.  IW—cardiac ischemic kidney 
tissue with WTACE2; CW—kidney tissue i.p. injected with WTACE2 without 





















Figure 32.  Bar graph representing the mean densitometer readings of Western 
blots for caspase 9.  Kidney samples from animals that underwent induced 
cardiac ischemia after i.p. injections of WTACE2 (Isc WTACE) had a mean 
densitometer reading of 3.9, an approximate 1.5 fold increase of caspase 9 levels 
over control.  Kidney samples from animals that underwent induced cardiac 
ischemia after i.p. injections of vehicle only (Isc Vehicle) had a mean 
densitometer reading of 5.1, an approximate 2 fold increase in caspase 9 levels 
over control.  As with caspase 2 and 3, results of Western blot analysis of caspase 
9 indicates there is still apoptotic signaling although TNF release has been 
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Figure 33.  PARP. Western blot exposed film showing the 24 kD band for the 
cleaved fragment of PARP.  This blot as well illustrates there is apoptotic 
signaling in the kidney after only 15 minutes of cardiac ischemia regardless of 
the inhibition in the release of TNF.    IW—cardiac ischemic kidney tissue with 
WTACE2; CW—kidney tissue i.p. injected with WTACE2 without induced 



















Figure 34.  Bar graph representing the mean densitometer readings of Western 
blots for PARP.  Kidney samples from animals that underwent induced cardiac 
ischemia after i.p. injections of WTACE2 (Isc WTACE) had a mean 
densitometer reading of 1.5, an approximate 2 fold increase of cleaved PARP 
levels over control.  Kidney samples from animals that underwent induced 
cardiac ischemia after i.p. injections of vehicle only (Isc Vehicle) had a mean 
densitometer reading of 2.8, an approximate 3.5 fold increase in cleaved PARP 
levels over control.  As with caspase 2, 3, and 9 results of Western blot analysis 
of PARP indicates there is still apoptotic signaling although TNF release has 
been inhibited, but not to the degree seen when TNF release is not restricted.   
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minutes of cardiac ischemia regardless of the inhibition of TNF release.  The mean 
densitometer readings of these Western blots are represented in the bar graph in Figure 
34.  Kidney samples of animals that experienced cardiac ischemia after WTACE2 
injections had a mean densitometer reading of 1.5, an approximate 2 fold increase of 
cleaved PARP levels over the control mean densitometer of .8.  Kidney samples from 
animals that experienced cardiac ischemia after injections of vehicle only had a mean 
densitometer reading of 2.8, and approximate 3.5 fold increase in cleaved PARP over 
control.  These results of PARP reflect that seen with caspase 2, 3, and 9 where apoptotic 
signaling is still apparent after the inhibition TNF, but not to the degree seen when TNF 
release is not restricted. 
To continue the investigation on the importance of TNF in cardiorenal syndrome, 
we eliminated the cardiac ischemic event and i.p. injected TNF with two milliliters of 
normal saline in one group of rats, or i.p. injected simply two milliliters of normal saline 
in a second group of rats.  It was decided to do this study because the myocardium is 
known for releasing more then just the cytokine TNF [3], [4], [5].  The infusion of TNF 
with out an ischemic event will give a clearer picture of the role TNF plays in injury to 
the kidney since none of the other cytokines will be released as a result of cardiac 
ischemia.   
MAP were continually monitored on all the animals in the TNF infusion studies.  
Figure 35 shows the graph of the MAP for the two groups (control and TNF infused) 
showing there is no statistical significant difference between or within the two groups.  
Blood pressures in these animals stayed at a level that we were confidant organ ischemia 













Figure 35.  Mean blood pressures for animals in the TNF infusion studies.  As 
can be seen there is no significant difference between the control animal and the 
TNF infused animals.  MAP remained in a range where there was proper 
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Figure 36.  Western blot exposed film showing even loading determine by 
probing blot with the primary antibody of actin.  This procedure was done for 








Caspase 2 Caspase 3 Caspase 9 PARP 
Control 1.2 1.4 2.6 .8 
Inf Control 1.6 .9 3.9 1.6 
Ischemic 8.6 4.6 8.4 5.4 
TNF Inf 4.0 1.3 4.7 3.4 
 
Table 2.  Mean densitometer readings of Western blot analysis of kidney tissue 
with no treatment (Control), kidney tissue from animals infused with normal 
saline alone (Inf Control), cardiac ischemic kidney tissue (Ischemic), and kidney 
tissue from animals infused with TNF (TNF Inf).  This table illustrates there is an 
increase in apoptotic signaling due to TNF infusion over control, but not to the 
degree seen with kidney tissue from animals who underwent coronary occlusion.  
 
Figure 36 shows an example of a Western blot exposed film probed with the 
primary antibody actin to illustrate even protein loading.  As with our other studies, the 
density of the bands of interest from exposed film were measured on a densitometer to 
calculate even loading. This procedure was done on each blot for the TNF infusion 
studies. 
Western blot analysis of kidney samples from the TNF infusion studies showed 
there is some apoptotic signaling due to TNF alone, but not to the degree found in the 
cardiac ischemic kidney tissues seen in the cardiac ischemic assays of this chapter.  These 
results suggest that TNF is not the only source for increased apoptosis in the kidney due 
to cardiac ischemia.   Table 2 shows the mean densitometer readings from both cardiac 
ischemia and TNF infusion studies.  Interestingly, these results closely resemble that of 
the WTACE2 studies (Table 1):  when TNF is inhibited there is a decrease in apoptosis 
activity again indicating that TNF is not the only influence driving apoptotic signaling in 










Figure 37.  Western blot exposed film showing the 24-26 kD band for active 
caspase 2.  This blot illustrates there is apoptotic signaling in the kidney tissue 
from animals infused with TNF (TNF Inf.), and it is clear that the caspase 2 






















Figure 38.   Bar graph representing the mean densitometer readings of Western 
blots for caspase 2.  Kidney samples from animals that were infused with TNF  
(TNF Inf) had a mean densitometer reading of 4.0, an approximate 2.5 fold 
increase of caspase 2 levels over control kidney tissue (Control Inf) of animals 
infused with normal saline alone with a mean densitometer reading of 1.6, but 
there is not the degree of caspase 2 signaling as that seen in cardiac ischemic 
kidney samples (Ischemic) showing a mean densitometer reading of 8.6.  These 
results indicate that although TNF does play a role in apoptotic signaling in the 
kidney after cardiac ischemia it is not the sole participant.   
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An example of a caspase 2 Western blot exposed to film is shown in Figure 37.  
The activated fragments of caspase 2 fall between 24-26 kD, and as illustrated in this 
Western blot, there is a distinct band with TNF infusion compared to an undetectable 
band with the kidney tissue taken from animals injected with normal saline alone.  The 
caspase 2 Western blots of the TNF infusion studies look very similar to that found in the 
caspase 2 Western blots of the ischemic studies of this chapter, but the caspase 2 signal 
read by the densitometer is not as strong with the TNF infusion studies as that of the 
ischemic studies shown in Figure 38.  Caspase 2 Western blot analysis for the TNF 
infusion studies shows an increase in a mean densitometer reading of 4.0 compared to the  
control mean densitometer reading of 1.6, producing an approximate 2.5 fold increase in 
caspase 2 levels in the TNF infused kidney samples over that of the infusion control 
tissues.   This caspase 2 increase did not equal the 7-fold increase in the cardiac ischemic 
kidney tissue over control.    
 As mentioned before, caspase 3 plays a dominate role in apoptosis.  It is the target 
of caspase 8, caspase 2, and caspase 9 complex shown in Figure 1 [47],  [2], [22], [48], 
[20].  Figure 39 illustrates an example of a Western blot exposed film showing the 17 kD 
band for active caspase 3, and like caspase 2, this blot indicates a substantial increase in 
caspase 3 levels in the kidney tissue from animals infused with TNF over that of tissue 
from animals infused with normal saline alone.  Mean densitometer reading of the 
Western blots for caspase 3 with these same kidney tissue samples is 1.3.  This is an 
approximate 1.5 fold increase of caspase 3 levels over kidney tissue of animals infused 














Figure 39.   Western blot exposed film showing the 17 kD band for active 
caspase 3.  Like that of caspase 2, this blot illustrates there is apoptotic signaling 
in the kidney tissue from animals infused with TNF (TNF Inf.), and it is clear 
that the caspase 3 signaling is greater than that of the animals infused with 
























Figure 40.  Bar graph representing the mean densitometer readings of Western 
blots for caspase 3.  Kidney samples from animals that were infused with TNF  
(TNF Inf) had a mean densitometer reading of 1.3, an approximate 1.5 fold 
increase of caspase 3 levels over control kidney tissue (Control Inf) of animals 
infused with normal saline alone with a mean densitometer reading of .9, but 
again as there is with caspase 2, caspase 3 signaling is not as great as that seen in 
cardiac ischemic kidney samples (Ischemic) showing a mean densitometer 




again as reflected in Figure 40, caspase 3 signaling, like caspase 2, is not as great as that 
seen in cardiac ischemic kidney samples with a mean densitometer reading of 4.6. 
 In our studies we chose caspase 9 to indicate mitochondria amplification of 
apoptosis via the TNF pathway shown in Figure 1—caspase 8 activation → Bid cleavage 
→ mitochondrial release of cytochrome c complexing with Apaf-1 and pro-caspase 9 → 
activation of caspase 9 → caspase 3 activation [48], [36],[46].  Figure 41 shows an 
example of Western blot exposed films probed with active caspase 9.  This blot illustrates 
that in fact there is mitochondria amplification of apoptosis indicated by the increase in 
levels of active caspase 9 from kidney tissues harvested from animals who under went 
TNF infusion over the control animal tissue.  Figure 42 demonstrates however, that this 
amplification is not as great as that seen in the kidney tissue from cardiac ischemic 
kidney samples.  The mean densitometer reading of TNF infused tissue for caspase 9 was 
4.7, an approximate 1.2 fold increase over control kidney tissue of animals infused with 
normal saline alone having a mean densitometer reading of 3.9, but not as high as the 
kidney tissue from cardiac ischemic tissue which show a densitometer reading of 8.4.  
 The cleavage of PARP has been found to be a sensitive parameter of apoptosis 
and can be detected within 15 minutes [56].  Therefore, the cleaved form of PARP has 
become the research hallmark for indicating apoptosis [20], [50], [2], [49], [56].  It has 
also been suggested that cleaved PARP can contribute to the machinery of apoptosis by 
either the 89 kD fragment exhausting the cell of needed energy or by the 24 kD fragment 
blocking DNA repair [56], [62], [63], [64].    Figure 43 is an example of Western blot 
exposed film showing the small-cleaved fragment of 24 kD band of PARP.  This blot 
illustrates there  is  an  increase in apoptotic signaling  in  the  kidney  tissue from animals  
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Figure 41.  Western blot exposed film showing the 10 kD (the fragment cleaved 
by caspase 3) band for active caspase 9.  Like that of caspase 2 and 3, this blot 
illustrates there is apoptotic signaling amplified via the mitochondria in the 
kidney tissue from animals infused with TNF (TNF Inf.), and it is apparent that 
the caspase 9 signaling is greater than that of the animals infused with normal 





















Figure 42.   Bar graph representing the mean densitometer readings of Western blots 
for caspase 9.  Kidney samples from animals that were infused with TNF  (TNF Inf) 
had a mean densitometer reading of 4.7, an approximate 1.2 fold increase of caspase 
9 levels over control kidney tissue (Control Inf) of animals infused with normal 
saline alone with a mean densitometer reading of 3.9, but again as there is with 
caspases 2 and 3, signaling is not as great as that seen in cardiac ischemic kidney 
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Figure 43.  Western blot exposed film showing the small cleaved fragment of 24 
kD  band of  PARP.  Once again, this blot illustrates there is apoptotic signaling 
in the kidney tissue from animals infused with TNF (TNF Inf.), and the PARP 





















Figure 44.  Bar graph representing the mean densitometer readings of Western 
blots for PARP.  Kidney samples from animals that were infused with TNF  
(TNF Inf) had a mean densitometer reading of 3.4, an approximate 2.1 fold 
increase of cleaved PARP levels over control kidney tissue (Control Inf) of 
animals infused with normal saline alone with a mean densitometer reading of 
1.6.  The TNF Inf. kidney tissue PARP signaling is not as great as that seen in 
cardiac ischemic kidney samples (Ischemic) showing a mean densitometer 
reading of 5.4.  Yet again, PARP signaling shows the same pattern as that of the 
other apoptotic indicators used in these studies (caspases 2, 3, and 9) 
demonstrating that there is more than just TNF causing injury to the kidney in 




infused with TNF over that of the animals infused with normal saline alone.  This is 
much like the results seen with Western blots of caspase 2, caspase 3, and caspase 9.  
Figure 44 is a bar graph representing the mean densitometer readings of Western blots for 
PARP.  As shown, the kidney samples from animals infused with TNF had a mean 
densitometer reading of 3.4, an approximate 2.1 fold increase of cleaved PARP levels 
over control kidney tissue from animals infused with normal saline alone having a 
densitometer reading of 1.6.   Once again the same pattern seen with caspase 2, caspase 3, 
and caspase 9, demonstrates apoptotic signaling, indicated here by PARP, is not as great 
in  TNF  infused kidney tissue as that seen in cardiac ischemic kidney samples showing 
amean densitometer reading of 5.4.  These TNF infusions studies along with the TNF 
inhibition studies (of this same chapter) are indicative that TNF does cause injury to the 
kidney but there is participation of other players causing a magnification of renal injury 




 The purpose of this study was to look at the consequence of cardiac ischemia on 
renal tissue as well as investigate the role of TNF in this process.  We have demonstrated 
through Western blot analysis for the fist time that cardiac ischemia can cause renal 
injury determined by the levels of apoptotic signaling.  These cardiac ischemic studies 
illustrate that in as little as 15 minutes of coronary occlusion, without reperfusion, there 
are increased levels of the apoptotic indicators active caspases 2, 3 and 9.     These same 
indicators are found in TNF receptor pathways leading to apoptosis (Figure 1).  Caspase 
2 can act either as an initiator activating caspase 3 and Bid, or act as an in effector and 
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directly cause apoptosis.  Because caspase 3 is targeted by caspases 8, 2, and 9 it is 
thought to play a dominant role in the apoptotic machinery [47],  [2], [22], [48], [20].  
Finally, the activation of caspase 9 can intimate a few things in the TNF-R pathway.  
Caspase 9 is an indicator of the mitochondria amplification of apoptosis, and with the 
pathway stimulated by TNF this can imply there is activation of caspase 8, caspase 2, and 
Bid.  Once caspase 8 or 2 is activated they can cleave Bid, which rapidly travels to the 
mitochondria causing the release of cytochrome c a factor necessary for the activation of 
caspase 9 [51], [47],  [2], [22], [48], [20].   With that being said, we see that there is 
injury to the kidney after cardiac ischemia as indicated by the apoptotic signaling, but the 
question still remains as to how important TNF is in the development of this renal injury. 
 Confident via TNF inhibition ELISA studies that TNF release was suppressed 
with the novel metalloproteinase inhibitor, WTACE2, after cardiac ischemia, we 
continued with the Western blot analysis comparing tissue that TNF was inhibited to that 
tissue where it was not.  We find that although TNF is inhibited, there appears to be 
continued apoptotic signaling in the kidney as indicated by increased levels of active 
caspases 2, 3, and 9, as well as the early marker for apoptosis cleaved PARP.   But as 
reveled by these investigations, the levels of these apoptosis indicators did not increase to 
the same degree as that seen in the cardiac ischemic kidney tissue.   These TNF inhibition 
studies imply that TNF does play a role in renal injury after cardiac ischemia, but is not 
the sole participant. 
 The myocardium is known to be a major source of the cytokines IL-1, IL-6, and 
IL-8 along with TNF  [6], [5].  Release of these cytokines under myocardial stress such as 
ischemia, can cause renal injury [4], [5].   So carrying the TNF investigation a step 
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further, our lab eliminated the cardiac ischemic event and infused TNF alone to give a 
clearer picture of the function of TNF in renal injury due to cardiac ischemia by reducing 
the possible influence of other cytokines.  Through Western blot analysis we discovered 
once more that TNF alone can cause the rise in apoptotic signaling as determined by 
increased levels of caspases 2, 3, and 9, as well as cleaved PARP, but again, the increase 
in signaling is not to the extent as that seen in renal tissue from animals who underwent 
15 minutes of cardiac ischemia.   
 In summary, these investigations show that cardiac ischemia can cause renal 
injury and that in 15 minutes of cardiac ischemia TNF does not act alone in injuring the 
kidney.  TNF may become a bigger player in renal injury if the duration of the ischemic 
event is increased or the myocardium is reperfused.   It has been shown in both these 
situations that TNF levels go up [3], [4], [5], [6], [8], [9], [10], but could it be that other 
cytokines go up as well?  Further research needs to be done to determine if in fact TNF is 
the major participant in the cause of renal dysfunction in cardiorenal syndrome.   
Investigations such as expanding the duration of cardiac ischemia as well as reperfusing 
the myocardium need to be done due to correlations made between the length of ischemia 
and the levels of cytokine release and myocardial reperfusion and the levels of cytokine 
release [6], [3], [4], [5].   Other infusion studies such as the ones done in our lab with 
TNF need to be done with other cytokines.  Elimination of cardiac ischemia and infusing 
one cytokine per assay could elucidate which cytokine plays a key role in renal injury or 
show renal injury is a combined effort of all cytokines as we find in our 15 minute 
cardiac ischemic model.   These continued studies are imperative for answers key to 
developing proper therapeutics to prevent renal injury due to myocardial ischemia.   
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Chapter VIII 
SUMMARY AND CONCLUSIONS  
 The purpose of these studies was to acquire a clearer understanding of cardiorenal 
syndrome.   Cardiorenal syndrome is a term created and used by clinicians who observed 
a connection between renal injury and an injured heart.  These same clinicians feel the 
cause of the renal injury is due to cytokines being released by the injured or ischemic 
myocardium [6], [7],  [3],  [4], but not until these studies has there been any research to 
support or disprove this theory.  Furthermore, it is thought that TNF is the most likely to 
induce renal dysfunction [3], and so, was the cytokine of interest in these studies. 
 The specific aims of this study were: 
Aim #1 – To quantitate the serum levels of the cytokine TNF after a myocardial 
infarction using an ultrasensitive TNF ELISA (Chapter VI). 
Aim #2 – To determine if apoptosis occurs in kidney cells as a result of cardiac 
ischemia by looking at the early marker of apoptosis, PARP, using Western 
blot analysis (Chapter V). 
Aim #3 – To examine which cell types in the kidney show activation of pro-
apoptotic proteins following cardiac ischemia assessed by 
immunohistochemistry probing for cleaved PARP and activated caspase 3 
(Chapter VI). 
Aim #4 – To investigate apoptotic signaling in kidney tissue after induced cardiac 
ischemia, as well as examine the role of TNF in these activities (Chapter VII), 
accomplished by performing: 
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a. Western Blot analysis on kidney tissue measuring the apoptotic proteins of 
caspases 2, 3, and 9  
b. Inhibition of TNF release via a metalloproteas inhibitor and determining 
apoptotic signaling by looking at caspases 2, 3, 9, and PARP using 
Western blot analysis 
c. TNF infusion studies without induced cardiac ischemia to determine levels 
of pro-apoptotic protein levels of caspases 2, 3, 9, and PARP. 
 One of our major concerns with inducing cardiac ischemia was to ensure the 
animals’ kidneys were properly perfused for the entire 15 minutes.  To make certain there 
was proper renal blood flow we continually monitored arterial pressure in the animals of 
all groups (controls, ischemic, TNF inhibition, and TNF infusion studies) by placing a 
catheter in the carotid artery attached to a computerized blood pressure transducer.    
Figures 4, 6, 9, 15, 23, and 35 are graphs of MAPs in these studies.  There was no 
evidence that arterial blood pressures decreased to a point where there was not sufficient 
renal perfusion throughout all the studies. 
 Since TNF became the focus of these studies, our first aim was to quantitate the 
serum levels of TNF after induced coronary ischemia (Chapter VI).   These studies were 
successful in measuring TNF pre and post 15-minute cardiac ischemia without 
reperfusion.  It was shown quantitatively that serum TNF levels consistently increase 
after cardiac ischemia was induced.  Our studies were consistent with other animal 
research showing the cytokine TNF does in fact go up due to myocardial infarction [8], 
[9], [10].  Interesting, we found the greater the area of ischemia the higher the levels of 
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TNF in the serum.  Wan et al. were also able to correlate the serum TNF levels with the 
extent of myocardial ischemia [4].    
 PARP is considered an early indicator and is an accepted marker for apoptosis 
[20], [50], [2], [49], [56].  Studies have shown that PARP cleavage can be seen within 15 
minutes of an insult [56].  Due to this early cleavage we used cleaved PARP as our 
indication of apoptosis for Aim #2 (Chapter V).  Via Western blot analysis we did indeed 
find an increase in both the cleaved products of PARP (89 kD and 24 kD) in renal tissue 
after 15 minutes of cardiac ischemia (Figure 7 and Figure 8); an approximate 6.75 fold 
increase of apoptotic activity.  It is yet to be determined if the increases in cleaved PARP 
found in these studies is enough to cause extensive renal damage, but there is clearly an 
increase in the initiation of apoptosis caused by cardiac ischemia without reperfusion. 
 These studies also demonstrated for the first time those renal cells most affected 
by an injured heart.  Using immunohistochemistry on renal tissue specially prepared, we 
looked at both kidneys from animals of the control group and ischemic group to achieve 
Aim #3 (Chapter VI).   Using the active forms of caspase 3 and PARP, we found that 
harm to the cardiac ischemic kidney samples appears to focus in the proximal tubules of 
the renal cortex (Figures 10, 11, 12, 13).  The apoptotic injury was not global but found 
in small patches of the proximal tubules throughout the cortical portion of the kidney.   
This finding would probably not have much effect on a healthy kidney, but for diseased 
or aged kidneys this loss of proximal tubules could be critical. 
 The final portion of these studies was to examine the role of TNF in the apoptotic 
activity found in Chapters V and VI (Aim #4).  In order to assess TNF we first looked at 
apoptotic signaling using Western blot analysis specifically looking at active forms of 
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caspases 3, 2, and 9 (activity known for TNF receptor signaling pathways [Figure 1]).  
Secondly, we inhibited the release of TNF and again looked at apoptotic activity via 
protein levels of active forms of caspases 3, 2, 9, plus cleaved PARP using Western blot 
analysis.  And finally, to carry the TNF investigation a step further, our lab eliminated the 
cardiac ischemic event and infused TNF alone to give a clearer picture of the function of 
TNF in renal injury due to cardiac ischemia.  It was our belief this procedure would 
reduce the possible influence of other harmful cytokines, which has been shown to be 
increase with the injured or ischemic myocardium.  Once again through Western blot 
analysis we looked at TNF apoptotic activity via caspases 2, 3, and 9, as well as cleaved 
PARP. 
 We found that there is an increase in apoptotic activity as seen with the increase 
levels of caspases 2, 3, and 9 in the cardiac ischemic kidney samples over that of control 
samples.  Table 3 shows mean densitometer readings of our Western blot analysis 
findings on apoptotic signaling.  This table shows a clear picture of apoptotic activity 
with increase levels of caspases 2, 3, and 9.  Caspase 2 had an approximate 7 fold 
increase over controls, caspase 3 shows an increase of approximately 3.3 fold over 
control, and caspase 9 activity increased approximately 3.2 fold over that of control.   
 Our investigation on the role of TNF in renal injury after a cardiac ischemic event 
shows that after 15 minutes of cardiac ischemia, TNF does not act alone in harming the 
kidney.   We found that although the release of TNF is inhibited, there is still an increase 
in apoptotic activity over that of controls (Table 1, Chapter VII).  This signaling did not, 
however, reach those levels seen with either the cardiac ischemic animals receiving 
vehicle only or the animals from the cardiac ischemic studies.  These findings were seen 
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with levels of caspases 2, 3, and 9, as well as levels of cleaved PARP.  Also reflected in 
Table 1 of Chapter VII is the control without TNF inhibitor and the control with TNF 
inhibitor showing very similar mean densitometer readings indicating the TNF inhibitor 
had no direct effect on the kidney tissue. 
 Finally, in order to investigate the importance of TNF in cardiorenal syndrome, 
we eliminated the cardiac ischemic event and i.p. injected 2ng of TNF for every 1ml of 
extracellular fluid diluted in two milliliters of normal saline in one group of rats, and i.p. 
injected two milliliters of normal saline only in a second group of rats.   By eliminating 
the release of other cytokines, known to be increased in serum after cardiac ischemia, we 
could center our research findings on just the effects of TNF on renal tissue.  What we 
found was very similar to that seen in the TNF inhibition studies.  There was an increase 
in apoptotic signaling (measured by levels of active caspases 2, 3, 9 as well as cleaved 
PARP) but not to the extent seen in the renal tissue harvested from animals that 
underwent coronary occlusion (Table 2, Chapter VII). 
 The investigations for Aim #4 show that cardiac ischemia can cause renal injury 
and that in 15 minutes of cardiac ischemia TNF does not act alone in injuring the kidney.  
We find this to be true by looking at the inhibition studies as well as the TNF infusion 
studies, neither of which showed apoptotic activity at the scale shown in the ischemic 
renal tissue. 
 In conclusion, our investigation of cardiorenal syndrome has given a better 
understanding of its mechanism of action.  1) We know that serum TNF goes up after an 
ischemic event as seen in Chapter IV;  2) we know there is an increase in apoptosis in 
renal  tissue after  cardiac  ischemia measured  by  the  early marker  of  cleaved PARP  
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Mean Densitometer Readings  
Samples Caspase 2 Caspase 3 Caspase 9 
Ischemia 8.6 4.6 8.4 
Control 1.2 1.4 2.6 
 
Table 3.  Mean densitometer readings of Western blot analysis of cardiac 
ischemic kidney tissue and controls (kidney samples of animals who did not 
undergo coronary artery occlusion).   This table demonstrates the increase in 
TNF activity as illustrated by the rise in levels of active caspases 2, 3, and 9. 
 
 
 (Chapter V);  3) for the first time we now know were the injury takes place in the kidney 
due to coronary occlusion as seen in our immunohistochemistry studies (Chapter VI);  4) 
and finally, we know now that TNF is not the only participant in renal injury (Chapter 
VII).  We feel that although we have enhanced our knowledge of cardiorenal syndrome 
there is much more research that needs to be done.   
 Our study protocol called for 15 minutes of ischemia without perfusion.  We feel 
a clearer story of the observed cardiorenal syndrome may arise should time for the 
coronary occlusion be extended.   It has been shown in other animal and human studies 
that the greater the duration of cardiac ischemia the higher the levels of serum TNF [8], 
[9], [10], [5].  Preliminary studies done in our lab found some increased damage to the 
kidney when we extended the duration of our study protocol to one hour (Figure 13).  
The damage was still in the cortical proximal tubules as found in the 15-minute protocol.  
The 15-minute method showed an increase in apoptotic activity, but actual damage was 
seen in the one-hour tissue slides. 
 Also, we feel that studies should be done examining renal tissue after reperfusion 
of the heart following coronary occlusion.  This type of procedure would be more 
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representative of clinicians’ findings with cardiorenal syndrome after CPB.  Research 
findings have shown a substantial increase in serum TNF levels after coronary 
reperfusion [8], [9], [10]. Furthermore, we believe with the extension of coronary 
occlusion with reperfusion that TNF may become a bigger participant in renal injury then 
what we measured in our studies (Chapter VII).  But with this in mind, there could also 
be an increase in serum levels of other harmful cytokines.  Additional research needs to 
be done to determine if TNF is in fact the major injury causing cytokine seen in 
cardiorenal syndrome, and further research needs to be done measuring other 
participating cytokines in this renal injury.   
 As mentioned in Chapter I, TNF-R activity is very complex.  Not only can the 
TNF-R activate apoptosis, but it can also initiate antiapoptotic activity [24], [43], [41], 
[70], [71], [42], [72].   Although there are many CPB procedures done, clinicians have 
only observed a small percentage of their patients who experience acute renal failure [3].  
It is our feeling this low percentage is due to the protective aspect of TNF.  Figure 45 is a 
simple illustration on the TNF-R pathway leading to cell life instead of cell demise.     
Literature shows that antiapoptotic proteins IAPs, A20, TRAF1 and TRAF2 are related to 
the TNF-R.  TRAF2 is activated by both TRADD and RIP, which then stimulates the 
activation of NF-κB.  The initiation of NF-κB can then upregulate IAPs, TRAF1, and 
A20.  TRAF1 is thought to enhance the recruitment of IAPs, and A20 can bind to and 
inhibit NF-κB as well as inhibit apoptosis by mechanisms still unclear [24].  IAPs 
prevent apoptosis by breaking into fragments that bind specifically to certain caspases 
[24], [43], [41], [70], [71], [42], [72].  In our lab, we did some preliminary studies on one 
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Figure 45.  TNF induced antiapoptotic pathway.  TNF binds to and activates the 
TNF-R.  Once the receptor is activated not only can it initiate apoptosis but also 
it can prevent it.  The recruitment of TRADD activates TRAV2 and RIP.  RIP 
and TRAV2 both activate NF-κB, which initiates the upregulation of IAPs, A20, 
and TRAV1.  TRAV1 enhances the recruitment of IAPs, and IAPs inhibit 
caspases such as caspases 3 and 9.  A20 inhibits NF-κB as well as directly 
inhibiting apoptosis 
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XIAP with caspases 3 and 9.  Using the same cardiac ischemic kidney tissues as used in 
the ischemic studies in Chapter VII, we investigated protein levels of XIAP by means of 
Western blot analysis.  What we found was, as the levels of caspase 3 and 9 increased, 
XIAP levels decreased in the same tissues.  This indicates that as needed, XIAP breaks 
into its fragments in order to combat against apoptosis by binding to specific caspases 
and preventing cell damage.  This is a delicate balance, as seen in most biological 
systems, determining a cell’s fate.   Research for a better understanding of theses 
pathways could give us mechanisms by which we could perhaps increase the initiation of 
antiapoptotic proteins to prevent cell destruction, or possibly block their activity and 
allow unwanted cells to die. 
World wide there is a continual growth of cardiovascular disease, and it is 
apparent that there will also be an increase in CBP surgeries.   With more patients 
undergoing CBP it stands to reason that the percentage of cardiorenal syndrome will 
further increase as well.  A greater understanding of the mechanism of action causing 
cardiorenal syndrome would greatly improve the outcomes of patients undergoing CBP 
without the added burden of acute renal dysfunction, or worse, renal failure.   To improve 
cardiac patients’ overall outcome from such events, these studies as well as further 
investigations, may provide treatments preventing the harmful effects caused by 
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